Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists

JP2024099528A5Active Publication Date: 2024-11-14BOEHRINGER INGELHEIM INT GMBH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024055696
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-16
Filing Date
2024-03-29
Publication Date
2024-11-14
Estimated Expiration
2041-11-12

AI Technical Summary

Technical Problem

Existing PAFR antagonists face challenges in achieving potent, selective, and stable inhibition of platelet activating factor receptors while maintaining favorable pharmacokinetic properties and avoiding toxicity, particularly for treating ocular diseases and inflammation-related conditions.

Method used

Development of novel cyclopentathiophene carboxamide derivatives that act as potent PAFR antagonists, exhibiting high selectivity, metabolic stability, and chemical stability, with the ability to bind melanin, leading to prolonged drug retention in the eye.

Benefits of technology

The compounds demonstrate enhanced efficacy in treating ocular diseases and inflammation by providing high potency, selectivity, and stability, with improved biodistribution and pharmacokinetic properties, suitable for treating conditions like dry and wet age-related macular degeneration and urticaria.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024099528000001
    Figure 2024099528000001
  • Figure 2024099528000002
    Figure 2024099528000002
  • Figure 2024099528000003
    Figure 2024099528000003
Patent Text Reader

Abstract

To provide novel platelet activating factor receptor antagonists.SOLUTION: Cyclopentathiophene carboxamides of formula (I.0) and pharmaceutically acceptable salts thereof can be used in methods for the treatment of diseases which can be influenced by antagonizing the activity mediated by the platelet activating factor receptor.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to novel cyclopentathiophene carboxamide derivatives and their pharma- ceutical acceptable salts, which are platelet activating factor receptor antagonists.Furthermore, the present invention relates to pharmaceutical compositions and combinations comprising said compounds, and their use in methods for treating diseases that can be affected by antagonizing platelet activating factor receptor.In particular, the pharmaceutical compositions of the present invention are suitable for the prevention and / or treatment of ophthalmic diseases, allergy and inflammation-related conditions and diseases, particularly dry and wet age-related macular degeneration, geographic atrophy, urticaria and NASH. [Background technology]

[0002] Platelet-activating factor (PAF) is an ether-phospholipid and the most potent lipid mediator known. PAF is synthesized constitutively or under specific stimuli by a variety of cells, such as platelets, macrophages, monocytes, neutrophils, basophils, eosinophils, mast cells, and endothelial cells. PAF, PAF-like lipids (PAFLL), and some oxidized phospholipids are structurally well-defined ligands of the PAF receptor (PAFR), a G protein-coupled receptor. Expression of PAFR is restricted in certain target cells of the immune, hemostatic, and inflammatory systems. The signaling functions of PAF are largely involved in acute and chronic inflammation in virtually all organs. PAF is believed to play a role in some inflammatory disorders, and may have great relevance in ophthalmic diseases, cardiovascular diseases, cancer, neurological and neurodegenerative disorders, renal disorders, liver diseases and allergies.Therefore, for example, the inhibition of PAFR activation by PAFR antagonists and / or inverse agonists is believed to be useful for treating a wide range of disorders that can be affected by antagonizing and / or inversely activating PAFR, for example, as mentioned hereinbefore and hereinafter.In particular, PAFR antagonists and / or inverse agonists should be useful for preventing or treating ophthalmic diseases, such as atrophic or wet age-related macular degeneration, and geographic atrophy or allergy, and inflammation-related disorders, such as urticaria and non-alcoholic steatohepatitis (NASH). Suitable PAFR antagonists and / or inverse agonists for therapeutic use should bind to PAFR potently and with high selectivity.PAFR antagonists and / or inverse agonists should be well absorbed from the gastrointestinal tract, have sufficient metabolic stability, and have favorable pharmacokinetic properties.They should be non-toxic and have been demonstrated to have no or few side effects.

[0003] For example, low molecular weight PAFR antagonists are known in the art, which are compounds described in European Patent Application Publication No. 0194416 and European Patent Application Publication No. 0254245 by Weber et al. (Med. Res. Rev.1989, 9, 181-218) and Summers et al. (Curr. Pharm. Des. 1995, 1, 161-190).The compounds of the thienotriazolodiazepine class disclosed therein are reported to undergo hydrolysis in acidic solution (e.g., Gallo et al. (J. Heterocyclic Chem. 1988, 25, 867-869), Legouin et al. (J. Heterocyclic Chem. 2000, 37, 127-129)). Some of these compounds have also been identified as acting as inverse agonists of PAFR (Dupre et al. (J. Pharm. Exp. Ther. 2001, 299, 1, 358-365), Cellai et al. (Exp. Hematol. 2009, 37, 1176-1185)).

[0004] Further methods useful for the synthesis and isolation of said and related compounds are disclosed in DE 4132763, EP 0388789, EP 0450504, U.S. Pat. No. 7015213, WO 2008 / 063667, Tahara et al. (Arzneimittel-forschung 1978, 28, 1153-1158), Sung et al. (Archiv der Pharmazie 1996, 329, 291-300), Fier et al. (Org. Lett. 2017, 19, 1454-1457) and Brenna et al. (Green Chem. 2017, 19, 5122-5130). Summary of the Invention

[0005] In a first aspect, the present invention provides a compound of formula (I.0) [ka] (In the formula, R 1 is C 1-4 -alkyl (optionally substituted with 1 to 3 F) and C 3-4 -R consisting of cycloalkyl 1 - selected from group G1, R 2 is R 2 - selected from group G1, R 2 -G1 group is F, Cl, Br, I, C 1-4 -alkyl (optionally substituted by 1 to 3 F or one -CN, one -OH or one -OC 1-4 -alkyl), 3-4 -Cycloalkyl, -CN, -CONH2, -CONH(C 1-4 -alkyl), -CON(C 1-4 -alkyl)2, -COOH, -COO-C 1-4 -Alkyl, OH, -OC 1-4 -alkyl (optionally substituted with 1 to 3 F), -S(O) r -C 1-4 -alkyl (r=0, 1 or 2), n is selected from the group n-G1 consisting of 0, 1, 2 and 3; R 3 is H and C optionally substituted by 1 to 5 F 1-4 -R consisting of alkyl 3 - selected from group G1, R 4 is C 1-6 -R consisting of alkyl 4 - selected from the group G1a, 1-6 -Alkyl is optionally substituted with 1 to 3 F; -CN, -CONH2, -CONH(C 1-4 -alkyl), -CON(C 1-4 -alkyl)2, -COOH, -COO-C 1-4 -Alkyl, C1-3 -Alkyl-CO-NH-, C 1-3 -Alkyl-S(=O)2-NH-, OH and -OC 1-3 -alkyl (optionally substituted by 1 to 3 F), or R 4 -C 0-3 -Alkylene-C 3-10 -cycloalkyl and -C 0-3 -Alkylene-C 3-10 -R consisting of heterocyclyl 4 - selected from group G1b; The alkylene may be substituted with 1 to 2 substituents selected from F and CH3. two H atoms of one >CH group of said alkylene may be replaced by an ethylene (-CH-CH-) bridge to form a cyclopropylene moiety >C(-CH-CH-), The cycloalkyl and heterocyclyl are saturated monocyclic or bicyclic ring systems, The heterocyclyl may be N, NH, >N(C 1-4 -alkyl), >NCO(C 1-4 -alkyl), >NS(=O)2(C 1-4 -alkyl) and O, and contains 1 to 2 ring members independently selected from >C=O and >S(=O) r (r=0, 1 or 2), However, the heterocyclyl may include NN, NO and NS (=O) between the ring members. r=1,2 does not contain any heteroatom-heteroatom bonds other than The cycloalkyl and heterocyclyl may be substituted with 1 to 2 F, and may be substituted with Cl, -CN, -CONH2, -CONH(C 1-4 -alkyl), -CON(C 1-4 -alkyl)2, -COOH, -COO-C 1-4 -Alkyl, OH, -OC 1-3 -alkyl (optionally substituted with 1 to 3 F), and C1-4 -Alkyl (with 1 to 3 F or -CN, OH, -OC 1-4 -alkyl) or R 4 -C 0-3 -Alkylene-phenyl and -C 0-3 -alkylene-heteroaryl 4 - selected from the group G1c; The alkylene may be substituted with 1 to 2 substituents selected from F and CH3. two H atoms of one >CH group of said alkylene may be replaced by an ethylene (-CH-CH-) bridge to form a cyclopropylene moiety >C(-CH-CH-), The heteroaryl is a 5-membered monocyclic ring containing one ring member selected from N, NH, O, and S, and may further contain 1 to 2 N ring members, or a 6-membered monocyclic ring containing 1 to 2 N ring members; The phenyl and heteroaryl are F, Cl, Br, C 3-4 -Cycloalkyl, -CN, -CONH2, -CONH(C 1-4 -alkyl), -CON(C 1-4 -alkyl)2, -COOH, -COO-C 1-4 -Alkyl, -NHCO-C 1-4 -Alkyl, -NHS(=O)2-C 1-4 -Alkyl, -S(=O) r -C 1-4 -Alkyl (r=0, 1 or 2), -OC 1-4 -alkyl (optionally substituted with 1 to 3 F), and C 1-4 -Alkyl (with 1 to 3 F, or -CN, OH and -OC 1-4 -alkyl) or R 3and R 4 is R 3 and R 4 R, taken together with the amide N atom to which they are attached, form a 3- to 8-membered saturated monocyclic heterocyclyl 3 / 4 -G1a group, 3-8 membered saturated monocyclic heterocyclyl is >NH, >N(C 1-4 -alkyl), >N(CO-C 1-3 -alkyl), >N(S(=O)2-C 1-3 -alkyl) and O, >C=O and >S(=O) r (r=0, 1 or 2), However, the heterocyclyl may include NN, NO and NS (=O) between the ring members. r=1,2 does not contain any heteroatom-heteroatom bonds other than The heterocyclyl is optionally substituted by 1 to 4 F. 1 to 4 C optionally substituted by 1 to 3 F 1-3 - optionally substituted by alkyl, Cl, -CN, -CONH2, -CONH(C 1-4 -alkyl), -CON(C 1-4 -alkyl)2, -COOH, -COO-C 1-4 -Alkyl, HO-C 1-3 -Alkylene-, C 1-3 -Alkyl-OC 1-3 -Alkylene-, C 1-3 -Alkyl-CO-NH-, C 1-3 -Alkyl-S(=O)2-NH-, OH and C 1-3 -alkyl-O- (optionally substituted by 1 to 3 F), or R 3 and R 4 is R 3 and R 4together with the amide N atom to which they are attached form a 5- to 12-membered saturated bicyclic heterocyclyl; R 3 / 4 -G1b group, wherein the 5- to 12-membered saturated bicyclic heterocyclyl is >N-, >NH, >N(C 1-4 -alkyl), >N(CO-C 1-3 -alkyl), >N(S(=O)2-C 1-3 -alkyl) and O, >C=O and >S(=O) r (r=0, 1 or 2), However, the heterocyclyl may include NN, NO and NS (=O) between the ring members. r=1,2 does not contain any heteroatom-heteroatom bonds other than The heterocyclyl is optionally substituted by 1 to 6 F. 1 to 4 C optionally substituted by 1 to 3 F 1-3 - optionally substituted by alkyl, Cl, -CN, -CONH2, -CONH(C 1-4 -alkyl), -CON(C 1-4 -alkyl)2, -COOH, -COO-C 1-4 -Alkyl, HO-C 1-3 -Alkylene-, C 1-3 -Alkyl-OC 1-3 -Alkylene-, C 1-3 -Alkyl-CO-NH-, C 1-3 -Alkyl-S(=O)2-NH-, OH and C 1-3 -alkyl-O-, or R 3 and R 4 is R 3 and R 4 together with the amide N atom to which they are attached form a 7- to 12-membered fused bicyclic ring system; R 3 / 4 - selected from the group G1c; said bicyclic ring system being a heterocyclyl or heteroaryl consisting of one non-aromatic ring and one aromatic ring; The non-aromatic ring contains the amide N atom and is selected from the group consisting of =N-, >N-, >NH, >N(C 1-4 -alkyl), >N(CO-C 1-3 -alkyl), >N(S(=O)2-C 1-3 -alkyl) and O, and may further contain 1 to 2 ring members independently selected from >C=O and >S(=O) r (r=0, 1 or 2), with the proviso that NN, NO and NS (=O) are not included between the members of said non-aromatic ring. r=1,2 There are no heteroatom-heteroatom bonds other than the aromatic ring is selected from a 5-membered monocyclic ring containing one ring member selected from NH, N, O and S, which may further contain 1 to 2 N ring members, and a 6-membered monocyclic ring containing 0, 1 or 2 N ring members; the bicyclic ring system is optionally substituted by 1 to 4 F; 1 to 4 C optionally substituted by 1 to 3 F 1-3 - optionally substituted by alkyl, Cl, -CN, -CONH2, -CONH(C 1-4 -alkyl), -CON(C 1-4 -alkyl)2, -COOH, -COO-C 1-4 -Alkyl, HO-C 1-3 -Alkylene-, C 1-3 -Alkyl-OC 1-3 -Alkylene-, C 1-3 -Alkyl-CO-NH-, C 1-3 -Alkyl-S(=O)2-NH-, OH and C 1-3 -alkyl-O-(optionally substituted by 1 to 3 F), Unless otherwise specified in any definition referred to herein earlier, any alkyl or alkylene group may be straight chain or branched. Isomers, stereoisomers, tautomers, metabolites, prodrugs, solvates, hydrates, cocrystals, and salts thereof, particularly pharma- ceutically acceptable salts thereof, or combinations thereof. Regarding.

[0006] In a second aspect, the present invention relates to a pharmaceutical composition comprising one or more compounds of formula (I.0) as defined hereinbefore or hereinafter, or a pharma- ceutically acceptable salt thereof, optionally together with one or more inert carriers and / or diluents.

[0007] In a third aspect, the present invention relates to a pharmaceutical composition comprising one or more compounds of formula (I.0) as defined hereinbefore or hereinafter, or a pharma- ceutically acceptable salt thereof, and one or more additional therapeutic agents, optionally together with one or more inert carriers and / or diluents.

[0008] In a fourth aspect, the present invention relates to a compound of formula (I.0) as defined hereinbefore or hereinafter, or a pharma- ceutically acceptable salt thereof, for use as a medicament.

[0009] In a fifth aspect, the present invention relates to a method for the treatment of a disease or condition that can be affected by antagonizing the platelet activating factor receptor, in a patient in need thereof, comprising the step of administering to the patient one or more compounds of formula (I.0) as defined hereinbefore or hereinafter, or a pharma- ceutically acceptable salt thereof. Furthermore, the invention relates to the use of one or more compounds of formula (I.0) as defined hereinbefore or hereinafter, or a pharma- ceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a disease or condition that can be affected by antagonizing the platelet activating factor receptor. Furthermore, the invention relates to a compound of formula (I.0) as defined hereinbefore or hereinafter, or a pharma- ceutically acceptable salt thereof, for use in a method of treating a disease or condition that can be affected by antagonizing the platelet activating factor receptor in a patient in need thereof. Further aspects of the present invention will be apparent to those skilled in the art from the foregoing and following description as well as from the examples directly.

[0010] Common Terms and Definitions Terms not specifically defined herein should be given the meanings that would be given to those terms by one of ordinary skill in the art in light of this disclosure and the context. However, as used herein, unless specified to the contrary, the following terms have the meanings indicated and follow the following conventions: The terms "compound according to the invention", "compound of formula (I.0)", "compound of the invention" and the like mean compounds of formula (I.0) according to the invention, including their tautomers, stereoisomers and mixtures thereof, and salts thereof, particularly pharma-ceutically acceptable salts thereof, as well as solvates, hydrates and co-crystals of such compounds, including solvates, hydrates and co-crystals of such tautomers, stereoisomers and salts thereof. Similarly, unless specifically indicated otherwise, throughout this specification and the appended claims, a given chemical formula or name is intended to encompass tautomers, and all stereoisomers, optical isomers, and geometric isomers (e.g., enantiomers, diastereomers, E / Z isomers, etc.), as well as racemates thereof, as well as mixtures of different ratios of the individual enantiomers, mixtures of diastereomers, or mixtures of any of the above-mentioned forms in which such isomers and enantiomers exist, as well as salts (including pharma- ceutically acceptable salts thereof), and solvates thereof (e.g., solvates of the free compounds or hydrates, including solvates of salts of the compounds). The phrase "pharmacologically acceptable" is used herein to refer to compounds, substances, compositions and / or dosage forms that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without undue toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio. As used herein, "pharmaceutically acceptable salts" refers to derivatives of the disclosed compounds, where the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, inorganic or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. For example, such salts include salts from benzenesulfonic acid, benzoic acid, citric acid, ethanesulfonic acid, fumaric acid, gentisic acid, hydrobromic acid, hydrochloric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, 4-methyl-benzenesulfonic acid, phosphoric acid, salicylic acid, succinic acid, sulfuric acid, and tartaric acid. The pharma- ceutically acceptable salts of the present invention can be synthesized from the parent compounds that contain a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or free base forms of these compounds with a sufficient amount of the appropriate base or acid in water or in an organic diluent such as ether, EtOAc, EtOH, isopropanol or MeCN, or mixtures thereof. For example, salts of acids other than those mentioned above that are useful for purifying or isolating the compounds of the invention (eg, trifluoroacetates) also form part of this invention. When a compound of the invention is depicted in the form of a chemical name and as a formula, in the event of any discrepancy, the formula shall prevail.

[0011] In the groups, radicals or moieties defined below, the number of carbon atoms is often specified preceding the group, e.g., C 1-6 -Alkyl means an alkyl group or radical having 1 to 6 carbon atoms. An asterisk may be used in a subformula to indicate a bond that is attached to a defined core molecule; for example, if there is more than one point of attachment, i.e. more than one asterisk, in a subformula, these asterisks may be further specified by a parenthetical indication of the attachment portion of the core molecule. The naming of the atoms of a substituent begins with the atom closest to the core or group to which the substituent is attached.

[0012] For example, the term "3-carboxypropyl group" represents the following substituent: [ka] where the carboxy group is attached to the third carbon atom of the propyl group. The term "1-methylpropyl-", "2,2-dimethylpropyl-" or "cyclopropylmethyl-" represents the group:

[0013] [ka]

[0014] The term "substituted," as used herein, means that any one or more hydrogens on the specified atom, radical, or moiety are replaced with one selected from the indicated group, provided that the normal valence of the atom is not exceeded and that the substitution results in an acceptably stable compound. In the definitions of groups, terms such as "each of the X, Y and Z groups may be optionally substituted" means that each of the X groups, each of the Y groups and each of the Z groups may be optionally substituted as defined, either as an individual group or as part of the group of which each is composed. ex , H, C 1-3 -Alkyl, C 3-6 -Cycloalkyl, C 1-3 -Alkyl-C 3-6 -Cycloalkylene- or C 1-3-alkyl-O-, each alkyl group being one or more L ex " may be substituted with" in each of the above groups containing the term alkyl, i.e. the group C 1-3 -Alkyl, C 1-3 -Alkyl-C 3-6 -Cycloalkylene- and C 1-3 In each of the -alkyl-O-, the alkyl portion is as defined ex It means that it may be substituted by:

[0015] The term “C 1-n "-alkyl" (n is an integer greater than 1), either alone or in combination with another radical, means a linear or branched acyclic saturated hydrocarbon radical having 1 to n carbon atoms. For example, the term C 1-5 -Alkyl is H3C-, H3C-CH2-, H3C-CH2-CH2-, H3C-CH(CH3)-, H3C-CH2-CH2-CH2-, H3C-CH2-CH(CH3)-, H3C-CH(CH3)-CH2-, H3C-C(CH3)2-, H3C-CH2-CH2-CH2-CH2-, H3C-C Includes H2-CH2-CH(CH3)-, H3C-CH2-CH(CH3)-CH2-, H3C-CH(CH3)-CH2-CH2-, H3C-CH2-C(CH3)2-, H3C-C(CH3)2-CH2-, H3C-CH(CH3)-CH(CH3)- and H3C-CH2-CH(CH2CH3)-.

[0016] The term “C 1-n "-alkylene" (n is an integer greater than 1), either alone or in combination with another radical, means a divalent linear or branched acyclic alkyl radical having 1 to n carbon atoms. For example, the term C 1-4-Alkylene includes -CH2-, -CH2-CH2-, -CH(CH3)-, -CH2-CH2-CH2-, -C(CH3)2-, -CH(CH2CH3)-, -CH(CH3)-CH2-, -CH2-CH(CH3)-, -CH2-CH2-CH2-CH2-, -CH2-CH2-CH(CH3)-, -CH(CH3)-CH2-CH2-CH2-, -CH2-CH2-CH(CH3)-, -CH(CH3)-CH2-CH2-, -CH2-CH(CH3)-CH2-, -CH2-C(CH3)2-, -C(CH3)2-CH2-, -CH(CH3)-CH(CH3)-, -CH2-CH(CH2CH3)-, -CH(CH2CH3)-CH2-, -CH(CH2CH2CH3)-, -CH(CH2CH3)-CH2-, -CH(CH2CH2CH3)-, -CH(CH(CH3))2- and -C(CH3)(CH2CH3)-.

[0017] The term “C 3-n "-cycloalkyl" (n is an integer greater than 3), either alone or in combination with another radical, means an unbranched, cyclic saturated hydrocarbon radical having 3 to n carbon atoms. The cyclic group may be monocyclic, bicyclic, tricyclic, or spirocyclic, and is most preferably monocyclic. Examples of such cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclododecyl, bicyclo[3.2.1.]octyl, spiro[4.5]decyl, norpinyl, norbornyl, norcaryl, adamantyl, and the like.

[0018] The term "heterocyclyl" refers to any heterocyclic group selected from N, O, and S(O) r (r=0, 1 or 2), and optionally an aromatic ring of 3 to 14 ring atoms, wherein none of the heteroatoms are part of an aromatic ring. The term "heterocyclyl" is intended to include all possible isomers.

[0019] Thus, the term "heterocyclyl" includes the following exemplary structures, which are not depicted as radicals because each form may be attached via a covalent bond to any atom as long as appropriate valence is maintained: [ka] JPEG2024099528000005.jpg193169

[0020] The term "heteroaryl" refers to any heteroaryl group selected from N, O, or S(O) r (r=0, 1, or 2), and at least one of the heteroatoms is part of an aromatic ring. The term "heteroaryl" is intended to include all possible isomers.

[0021] Thus, the term "heteroaryl" includes the following exemplary structures, which are not depicted as radicals because each form may be attached via a covalent bond to any atom as long as appropriate valence is maintained: [ka]

[0022] The term "bicyclic ring system" means a group consisting of two joined cyclic moieties, including spirocyclic, fused and bridged ring systems. Many of the terms presented above may be used repeatedly in the definitions of formulae or groups and in each case have, independently of one of the meanings presented above. The terms "treatment" and "treating" as used herein include both therapeutic, i.e., curative and / or palliative, and prophylactic, i.e., preventative, treatment.

[0023] Therapeutic treatment refers to the treatment of patients who have already developed one or more of the above conditions in their initial, acute or chronic form.Therapeutic treatment can be symptomatic treatment to alleviate the symptoms of a particular symptom, or causal treatment to reverse or partially reverse the symptom state or to stop or slow down the progression of the disease. Prophylactic treatment ("prophylaxis") refers to treating a patient at risk of developing one or more of the above conditions prior to the clinical onset of the disease, so as to reduce said risk.

[0024] The terms "treatment" and "treating" include the administration of one or more active compounds to prevent or delay the onset of symptoms or complications, and to prevent or delay the onset of a disease, condition or disorder and / or to eliminate or control a disease, condition or disorder, as well as to alleviate symptoms or complications associated with a disease, condition or disorder. Where the present invention refers to a patient in need of treatment, the invention is primarily concerned with treatment in mammals, particularly humans.

[0025] The term "therapeutically effective amount" means an amount of a compound of the present invention that (i) treats or prevents a particular disease or condition, (ii) attenuates, ameliorates or eliminates one or more symptoms of a particular disease or condition, or (iii) prevents or delays the onset of one or more symptoms of a particular disease or condition described herein. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0026] The present invention discloses novel cyclopentathiophene carboxamide derivatives that are effective platelet-activating receptor (PAFR) antagonists and have favorable pharmacological and pharmacokinetic properties for their use as medicaments to prevent or treat diseases and / or conditions that can be affected by PAFR antagonism, including, but not limited to, ocular diseases and inflammation-related conditions and diseases, particularly geographic atrophy, wet age-related macular degeneration and allergies. The compounds of the present invention may realize several advantages, such as increased potency, increased metabolic and / or chemical stability, increased selectivity, safety and tolerability, increased solubility, increased permeability, desirable plasma protein binding, enhanced bioavailability, improved pharmacokinetic profile, and the potential to form stable salts.

[0027] Compounds of the Invention In a first aspect of the invention, there is provided a compound of formula (I.0) [ka] (In the formula, R 1 , R 2 , R 3 , R 4 It has been found that the compounds according to the present invention (where n and n are defined hereinbefore and hereinafter) are potent antagonists of PAFR and can exhibit advantageous properties in terms of selectivity, safety and tolerability, metabolic and / or chemical stability, pharmacokinetic and physicochemical characteristics, solubility, permeability, plasma protein binding, bioavailability, and the possibility of forming stable salts.In particular, they provide high in vitro potency as PAFR antagonists, and they show good in vivo potency in animal models of choroidal neovascularization.In addition, they are also found to act as PAFR inverse agonists in in vitro models, which may further contribute to their beneficial pharmacological effects.In addition, the compounds according to the present invention exhibit advantageous chemical stability, particularly even at low pH values, and advantageous solubility at various pH values, i.e. in acidic media, while their renal clearance remains reasonably low.

[0028] Thus, compounds of formula (I.0) as defined hereinbefore or hereinafter, or a pharma- ceutically acceptable salt thereof, are expected to be useful in the treatment of diseases and / or conditions which may be affected by PAFR antagonism. Surprisingly, the compound of formula (I.0) can also be shown to bind exclusively to melanin, which affects the biodistribution and pharmacokinetic properties of the compound; in particular, this leads to accumulation of the compound in the eye, resulting in prolonged drug retention. It is therefore expected that the compounds of the present invention are particularly suitable for the treatment of eye diseases.

[0029] Thus, according to one aspect of the invention, a compound of formula (I.0) [ka] (In the formula, R 1 , R 2 , R 3 , R 4 and n are defined hereinbefore and hereinafter). As well as isomers, stereoisomers, tautomers, metabolites, prodrugs, solvates, hydrates, co-crystals, and salts thereof, particularly pharma- ceutically acceptable salts thereof, are provided.

[0030] Unless otherwise stated, groups, residues and substituents, in particular R 1 , R 2 , R 3 , R 4 and n are defined hereinbefore and hereinafter. The substituent R 1 , R 2 , R 3 , R 4 Some of the preferred meanings of and n, as well as the phenyl substitution patterns and stereochemistry, are presented hereinafter as embodiments of the present invention. Any of these definitions and embodiments may be combined with each other.

[0031] R 1 : According to one embodiment, R 1 teeth, C 1-4 -alkyl (optionally substituted with 1 to 3 F) and C 3-4 -Cycloalkyl R consisting of1 - selected from group G1. According to another embodiment, R 1 teeth, CH3, CH2CH3, CH2CH2CH3, CHF2, CF3 and cyclopropyl R consisting of 1 - selected from Group G2. According to another embodiment, R 1 teeth, CH3, CH2CH3, CH2CH2CH3 and cyclopropyl R consisting of 1 - selected from the group G3. According to another embodiment, R 1 is R consisting of CH3 1 - selected from the group G4. According to another embodiment, R 1 is selected from CH2CH3, CH2CH2CH3 and cyclopropyl 1 - selected from the group G5.

[0032] R 2 : More than one substituent R 2 is present in compounds of formula (I.0), i.e. when n=2 or 3, R 2 R 2 -G1 group~R 2 - selected independently from the group G8. According to one embodiment, R 2 is R 2 - selected from group G1, R 2 -G1 group: F, Cl, Br, I, C 1-4 -alkyl (optionally substituted by 1 to 3 F or one -CN, one -OH or one -OC 1-4 -alkyl), 3-4 -Cycloalkyl, -CN, -CONH2, -CONH(C 1-4 -alkyl), -CON(C 1-4 -alkyl)2, -COOH, -COO-C 1-4-Alkyl, OH, -OC 1-4 -alkyl (optionally substituted with 1 to 3 F), -S(O) r -C 1-4 -alkyl (r=0, 1 or 2). According to another embodiment, R 2 is R 2 - selected from group G2, R 2 -G2 group: F, Cl, Br, C 1-3 -alkyl (optionally substituted by 2 or 3 F), cyclopropyl, -CN, -C 1-3 -Alkylene-OH, -C 1-2 -Alkylene-OC 1-2 -Alkyl, OH, -OC 1-3 -alkyl (optionally substituted by 2 or 3 F); 1-3 - alkyl. According to another embodiment, R 2 teeth, F, Cl, Br, CH3, CH2CH3, cyclopropyl, CF3, CH2OH, OH, OCH3 and S-CH3 R consisting of 2 - selected from the group G3. According to another embodiment, R 2 R is F, Cl and Br, preferably Cl. 2 - selected from the group G4. According to another embodiment, R 2 is R consisting of CH3 and CH2CH3 2 - selected from the group G5. According to another embodiment, R 2 R consists of cyclopropyl and CF 2 - selected from the group G6. According to another embodiment, R 2 is R consisting of CHOH and OH 2 - selected from the group G7. According to another embodiment, R 2 is an R consisting of OCH3 and S-CH3 2 - selected from the group G8.

[0033] n: According to one embodiment, n is selected from the group n-G1 consisting of 0, 1, 2 and 3. According to another embodiment, n is selected from the group n-G2 consisting of 0, 1 and 2. According to another embodiment, n is an n-G3 group consisting of 0. According to another embodiment, n is an n-G4 group consisting of 1. According to another embodiment, n is an n-G5 group consisting of 2.

[0034] Phenyl Substitution Pattern: In describing the substitution pattern of the phenyl ring shown in formula (I.0), the following carbon atom numbering is used: [ka]

[0035] In general, n substituents R 2 can each be bonded to any of the carbon atoms C-2 to C-6, and any combination thereof. For n=1, according to one embodiment, R 2 is attached to carbon atom 2. According to another embodiment, R 2 is attached to carbon atom 4. For n=2, according to one embodiment, R 2 One of the R 2 is attached to carbon atom 5. According to another embodiment, R 2 One of the R 2 is attached to carbon atom 5.

[0036] R 2 , n and phenyl substitution patterns: According to one embodiment, R 2 , n and the phenyl substitution pattern are such that the resulting substituted phenyl ring shown in formula (I.0) is [ka] The nucleotide sequence is selected from the Ph-G1 group consisting of:

[0037] According to another embodiment, R 2 , n and the phenyl substitution pattern are such that the resulting substituted phenyl ring shown in formula (I.0) is [ka] Preferably,

[0038] [ka] The compound is selected from the Ph-G2 group consisting of

[0039] According to another embodiment, R 2 , n and the phenyl substitution pattern are such that the resulting substituted phenyl ring shown in formula (I.0) is [ka] The nucleotide sequence is selected from the Ph-G3 group consisting of:

[0040] According to another embodiment, R 2 , n and the phenyl substitution pattern are such that the resulting substituted phenyl ring shown in formula (I.0) is [ka] The nucleotide sequence is selected from the group Ph-G4 consisting of:

[0041] According to another embodiment, R 2 , n and the phenyl substitution pattern are such that the resulting substituted phenyl ring shown in formula (I.0) is [ka] The nucleotide sequence is selected from the group Ph-G5 consisting of:

[0042] According to another embodiment, R 2 , n and the phenyl substitution pattern are such that the resulting substituted phenyl ring shown in formula (I.0) is [ka] The nucleotide sequence is selected from the Ph-G6 group consisting of:

[0043] According to another embodiment, R 2 , n and the phenyl substitution pattern are such that the resulting substituted phenyl ring shown in formula (I.0) is [ka] The nucleotide sequence is selected from the group Ph-G7 consisting of:

[0044] According to another embodiment, R 2 , n and the phenyl substitution pattern are such that the resulting substituted phenyl ring shown in formula (I.0) is [ka] The aryl group is selected so as to be selected from the group Ph-G8 consisting of:

[0045] R 3 and R 4 : According to one embodiment, R 3 teeth, H, and C optionally substituted with 1 to 5 F 1-4 -Alkyl R consisting of 3 - selected from group G1. According to another embodiment, R 3 teeth, H, and C optionally substituted with 1 to 3 F 1-3 -Alkyl R consisting of 3 - selected from group G2. According to another embodiment, R 3 is R consisting of H, CH3 and CH2CH2CH33 - selected from the group G3. According to one embodiment, R 4 is C 1-6 -R consisting of alkyl 4 - selected from the group G1a, 1-6 -Alkyl is optionally substituted with 1 to 3 F; -CN, -CONH2, -CONH(C 1-4 -alkyl), -CON(C 1-4 -alkyl)2, -COOH, -COO-C 1-4 -Alkyl, C 1-3 -Alkyl-CO-NH-, C 1-3 -Alkyl-S(=O)2-NH-, OH and -OC 1-3 -alkyl (optionally substituted by 1 to 3 F).

[0046] According to another embodiment, R 4 is C 1-6 -R consisting of alkyl 4 - selected from the group G2a, 1-6 -Alkyl is optionally substituted with 1 to 3 F; -CN, -CONH2, -CONH(C 1-2 -alkyl), -CON(C 1-2 -alkyl)2, -COOH, -COO-C 1-2 -Alkyl, C 1-2 -Alkyl-CO-NH-, C 1-2 -Alkyl-S(=O)2-NH-, OH and -OC 1-2 -alkyl (optionally substituted with 1 to 3 F).

[0047] According to another embodiment, R 4 is C 1-4 -R consisting of alkyl 4 - selected from the group G3a, 1-4 -Alkyl is optionally substituted with 1 to 3 F; -CN, -CONH2, -COOH, OH and -OC 1-2 -alkyl (optionally substituted with 1 to 3 F). According to another embodiment, R 4 is C 1-4 -R consisting of alkyl 4 -G4a group, C 1-4 -Alkyl is It may be substituted with one substituent selected from F, OH and OCF3.

[0048] According to another embodiment, R 4 teeth, [ka] R consisting of 4 - selected from the group G5a.

[0049] According to one embodiment, R 4 -C 0-3 -Alkylene-C 3-10 -cycloalkyl and -C 0-3 -Alkylene-C 3-10 -R consisting of heterocyclyl 4 - selected from group G1b; The alkylene may be substituted with 1 to 2 substituents selected from F and CH3. two H atoms of one >CH group of said alkylene may be replaced by an ethylene (-CH-CH-) bridge to form a cyclopropylene moiety >C(-CH-CH-), The cycloalkyl and heterocyclyl are saturated monocyclic or bicyclic ring systems, The heterocyclyl may be N, NH, >N(C 1-4 -alkyl), >NCO(C 1-4 -alkyl), >NS(=O)2(C 1-4 -alkyl) and O, and further containing 1-2 ring members independently selected from >C=O and >S(=O) r(r=0, 1 or 2), However, the heterocyclyl may include NN, NO and NS (=O) between the ring members. r=1,2 does not contain any heteroatom-heteroatom bonds other than The cycloalkyl and heterocyclyl may be substituted with 1 to 2 F, and may be substituted with Cl, -CN, -CONH2, -CONH(C 1-4 -alkyl), -CON(C 1-4 -alkyl)2, -COOH, -COO-C 1-4 -Alkyl, OH, -OC 1-3 -alkyl (optionally substituted with 1 to 3 F), and C 1-4 -Alkyl (with 1 to 3 F or -CN, OH, -OC 1-4 -alkyl).

[0050] According to another embodiment, R 4 -C 0-2 -Alkylene-C 3-8 -cycloalkyl and -C 0-2 -Alkylene-C 3-8 -R consisting of heterocyclyl 4 - selected from group G2b; The cycloalkyl and heterocyclyl are saturated monocyclic or bicyclic ring systems, The heterocyclyl contains one ring member selected from N, NH, and O, The cycloalkyl and heterocyclyl are optionally substituted with 1 to 2 F, and are optionally substituted with 1 to 2 substituents independently selected from Cl, -CN, OCH3, CH3 and CH2CH3.

[0051] According to another embodiment, R 4 -C 0-1 -Alkylene-C 3-6 -R consisting of cycloalkyl 4 - selected from the group G3b; The cycloalkyl is a saturated monocyclic or bicyclic ring system, The cycloalkyl may be substituted with 1 to 2 F, and may be substituted with one CH3 or CH2CH3.

[0052] According to another embodiment, R 4 teeth, [ka] R consisting of 4 -G4b group.

[0053] According to another embodiment, R 4 teeth, [ka] R consisting of 4 -G5b group.

[0054] According to another embodiment, R 4 teeth, [ka] R consisting of 4 -G6b group.

[0055] According to another embodiment, R 4 teeth, [ka] R consisting of 4 -G7b group. According to one embodiment, R 4 -C 0-3 -Alkylene-phenyl and -C 0-3 -alkylene-heteroaryl 4 - selected from the group G1c; The alkylene may be substituted with 1 to 2 substituents selected from F and CH3. two H atoms of one >CH group of said alkylene may be replaced by an ethylene (-CH-CH-) bridge to form a cyclopropylene moiety >C(-CH-CH-), The heteroaryl is a 5-membered monocyclic ring containing one ring member selected from N, NH, O, and S, and may further contain 1 to 2 N ring members, or a 6-membered monocyclic ring containing 1 to 2 N ring members; The phenyl and heteroaryl are F, Cl, Br, C 3-4 -Cycloalkyl, -CN, -CONH2, -CONH(C 1-4 -alkyl), -CON(C 1-4 -alkyl)2, -COOH, -COO-C 1-4 -Alkyl, -NHCO-C 1-4 -Alkyl, -NHS(=O)2-C 1-4 -Alkyl, -S(=O) r -C 1-4 -Alkyl (r=0, 1 or 2), -OC 1-4 -alkyl (optionally substituted with 1 to 3 F), and C 1-4 -Alkyl (with 1 to 3 F, or -CN, OH and -OC 1-4 -alkyl).

[0056] According to another embodiment, R 4 -C 0-2 -Alkylene-phenyl and -C 0-2 -alkylene-heteroaryl 4 - selected from the G2c group, The alkylene may be substituted with 1 to 2 CH3. two H atoms of one >CH group of said alkylene may be replaced by an ethylene (-CH-CH-) bridge to form a cyclopropylene moiety >C(-CH-CH-), The heteroaryl is a 5-membered monocyclic ring containing one ring member selected from N, NH, O, and S, and may further contain one N ring member, or a 6-membered monocyclic ring containing 1 to 2 N ring members; The phenyl and heteroaryl are F, Cl, Br, -CN, -OC 1-3 -alkyl (optionally substituted with 1 to 3 F), and C 1-3 -alkyl (optionally substituted by 1 to 3 F), or -CN and -OC 1-2 -alkyl.

[0057] According to another embodiment, R 4 -C 0-1 -Alkylene-phenyl and -C 0-1 -alkylene-heteroaryl 4 - selected from the group G3c, two H atoms of one >CH group of said alkylene may be replaced by an ethylene (-CH-CH-) bridge to form a cyclopropylene moiety >C(-CH-CH-), The heteroaryl is a 5- to 6-membered monocyclic ring containing one ring member =N-, optionally containing one ring member selected from =N-, >NH, S and O; The phenyl and heteroaryl may be substituted with 1 to 3 substituents independently selected from F, Cl, -CN, OCH3, OCHF2, OCF3, CH3, CHF2, and CF3.

[0058] According to another embodiment, R 4 teeth, [ka] R consisting of TIFF2024099528000025.tif112170 4 -G4c group.

[0059] According to another embodiment, R 4 teeth, [ka] R consisting of 4 -G5c group.

[0060] According to another embodiment, R 4 teeth, [ka] R consisting of 4 -G6c group.

[0061] According to another embodiment, R 4 teeth, [ka] R consisting of 4 -G7c group.

[0062] According to another embodiment, R 4 teeth, [ka] R consisting of 4 -G8c group.

[0063] According to one embodiment, R 3 and R 4 is R 3 and R 4 together with the amide N atom to which they are attached form a 3- to 8-membered saturated monocyclic heterocyclyl; R 3 / 4 -G1a group, 3-8 membered saturated monocyclic heterocyclyl is >NH, >N(C 1-4 -alkyl), >N(CO-C 1-3 -alkyl), >N(S(=O)2-C 1-3 -alkyl) and O, >C=O and >S(=O)r (r=0, 1 or 2), However, the heterocyclyl may include NN, NO and NS (=O) between the ring members. r=1,2 does not contain any heteroatom-heteroatom bonds other than The heterocyclyl is optionally substituted by 1 to 4 F. 1 to 4 C optionally substituted by 1 to 3 F 1-3 - optionally substituted by alkyl, Cl, -CN, -CONH2, -CONH(C 1-4 -alkyl), -CON(C 1-4 -alkyl)2, -COOH, -COO-C 1-4 -Alkyl, HO-C 1-3 -Alkylene-, C 1-3 -Alkyl-OC 1-3 -Alkylene-, C 1-3 -Alkyl-CO-NH-, C 1-3 -Alkyl-S(=O)2-NH-, OH and C 1-3 -alkyl-O- (optionally substituted with 1 to 3 F).

[0064] According to one embodiment, R 3 and R 4 is R 3 and R 4 together with the amide N atom to which they are attached form a 3- to 8-membered saturated monocyclic heterocyclyl; R 3 / 4 -G2a group, 3-8 membered saturated monocyclic heterocyclyl is >NH, >N(C 1-4 -alkyl), >N(CO-C 1-3 -alkyl), >N(S(=O)2-C 1-3 -alkyl) and O, and may further contain one ring member selected from >C=O and >S(=O) r (r=0, 1 or 2), However, the heterocyclyl does not have NS(=O) between the ring members.r=1,2 does not contain any heteroatom-heteroatom bonds other than The heterocyclyl is optionally substituted by 1 to 2 F. 1 to 4 C optionally substituted by 2 to 3 F 1-3 - optionally substituted by alkyl, Cl, -CN, -CON(C 1-4 -alkyl)2, -COO-C 1-4 -Alkyl, C 1-3 -Alkyl-OC 1-3 -Alkylene- and C 1-3 -alkyl-O-.

[0065] According to one embodiment, R 3 and R 4 is R 3 and R 4 together with the amide N atom to which they are attached, form a 4- to 6-membered saturated monocyclic heterocyclyl; Not adjacent to the amide N atom, >N(C 1-4 -alkyl) and O, R forms a 4- to 6-membered saturated monocyclic heterocyclyl. 3 / 4 - selected from the group G3a, The heterocyclyl is optionally substituted by 1 to 2 F. 1 to 4 C optionally substituted by 2 to 3 F 1-3 - optionally substituted by alkyl, Cl, -CN, -CON(C 1-4 -alkyl)2, -COO-C 1-4 -Alkyl, C 1-3 -Alkyl-OC 1-3 -Alkylene- and C 1-3 -alkyl-O-.

[0066] According to one embodiment, R 3 and R 4 is R 3and R 4 together with the amide N atom to which they are attached, form a 4- to 6-membered saturated monocyclic heterocyclyl; may contain one ring member O that is not adjacent to the amide N atom; R forms a 4- to 6-membered saturated monocyclic heterocyclyl. 3 / 4 - selected from the group G4a, The heterocyclyl is optionally substituted by 2 F and optionally substituted by 1 to 2 CH3.

[0067] According to one embodiment, R 3 and R 4 is R 3 and R 4 together with the amide N atom to which they are attached, are heterocyclyl; [ka] R 3 / 4 - selected from the group G5a.

[0068] According to one embodiment, R 3 and R 4 is R 3 and R 4 together with the amide N atom to which they are attached, are heterocyclyl; [ka] R 3 / 4 - selected from the group G6a.

[0069] According to one embodiment, R 3 and R 4 is R 3 and R 4 together with the amide N atom to which they are attached form a heterocyclyl [ka] Forming R3 / 4 - selected from the group G7a.

[0070] According to one embodiment, R 3 and R 4 is R 3 and R 4 together with the amide N atom to which they are attached, are heterocyclyl; [ka] R 3 / 4 - selected from the group G8a.

[0071] According to one embodiment, R 3 and R 4 is R 3 and R 4 together with the amide N atom to which they are attached form a 5- to 12-membered saturated bicyclic heterocyclyl; R 3 / 4 -G1b group, wherein the 5- to 12-membered saturated bicyclic heterocyclyl is >N-, >NH, >N(C 1-4 -alkyl), >N(CO-C 1-3 -alkyl), >N(S(=O)2-C 1-3 -alkyl) and O, >C=O and >S(=O) r (r=0, 1 or 2), However, the heterocyclyl may include NN, NO and NS (=O) between the ring members. r=1,2 does not contain any heteroatom-heteroatom bonds other than The heterocyclyl is optionally substituted by 1 to 6 F. 1 to 4 C optionally substituted by 1 to 3 F 1-3 - optionally substituted by alkyl, Cl, -CN, -CONH2, -CONH(C 1-4 -alkyl), -CON(C 1-4-alkyl)2, -COOH, -COO-C 1-4 -Alkyl, HO-C 1-3 -Alkylene-, C 1-3 -Alkyl-OC 1-3 -Alkylene-, C 1-3 -Alkyl-CO-NH-, C 1-3 -Alkyl-S(=O)2-NH-, OH and C 1-3 -alkyl-O-.

[0072] According to one embodiment, R 3 and R 4 is R 3 and R 4 together with the amide N atom to which they are attached form a 6- to 11-membered saturated bicyclic heterocyclyl; R 3 / 4 -G2b group, wherein the 6- to 11-membered saturated bicyclic heterocyclyl is >N-, >NH, >N(C 1-4 -alkyl), >N(CO-C 1-3 -alkyl), >N(S(=O)2-C 1-3 -alkyl) and O, >C=O and >S(=O) r (r=0, 1 or 2), However, the heterocyclyl may include NN, NO and NS (=O) between the ring members. r=1,2 does not contain any heteroatom-heteroatom bonds other than The heterocyclyl is optionally substituted by 1 to 6 F. 1 to 4 C optionally substituted by 1 to 3 F 1-3 - optionally substituted by alkyl, Cl, -CN, -CONH2, -CONH(C 1-4 -alkyl), -CON(C 1-4 -alkyl)2, -COOH, -COO-C 1-4 -Alkyl, HO-C 1-3 -Alkylene-, C 1-3-Alkyl-OC 1-3 -Alkylene-, C 1-3 -Alkyl-CO-NH-, C 1-3 -Alkyl-S(=O)2-NH-, OH and C 1-3 -alkyl-O-.

[0073] According to one embodiment, R 3 and R 4 is R 3 and R 4 together with the amide N atom to which they are attached form a 6- to 11-membered saturated bridged bicyclic or spiro bicyclic heterocyclyl; Not adjacent to the amide N atom, >N-, >NH, >N(C 1-4 -alkyl) and O, R forms a 6- to 11-membered saturated bridged bicyclic heterocyclyl or spiro bicyclic heterocyclyl. 3 / 4 - selected from the group G3b; with the proviso that said heterocyclyl does not contain any O-O bonds between ring members; The heterocyclyl is optionally substituted by 1 to 4 F. 1 to 2 C optionally substituted by 1 to 3 F 1-3 - optionally substituted by alkyl, Cl, -CN, -CON(C 1-4 -alkyl)2, -COO-C 1-4 -Alkyl, C 1-3 -Alkyl-OC 1-3 -Alkylene- and C 1-3 -alkyl-O-.

[0074] According to one embodiment, R 3 and R 4 is R 3 and R 4together with the amide N atom to which they are attached form a 6- to 10-membered saturated bridged bicyclic or spiro bicyclic heterocyclyl, which may contain one ring member O that is not adjacent to the amide N atom; R 3 / 4 -G4b group.

[0075] According to one embodiment, R 3 and R 4 is R 3 and R 4 together with the amide N atom to which they are attached, are heterocyclyl; [ka] R 3 / 4 -G5b group.

[0076] According to one embodiment, R 3 and R 4 is R 3 and R 4 together with the amide N atom to which they are attached form a 7- to 12-membered fused bicyclic ring system; R 3 / 4 - selected from the group G1c; said bicyclic ring system being a heterocyclyl or heteroaryl consisting of one non-aromatic ring and one aromatic ring; The non-aromatic ring contains the amide N atom and is selected from the group consisting of =N-, >N-, >NH, >N(C 1-4 -alkyl), >N(CO-C 1-3 -alkyl), >N(S(=O)2-C 1-3 -alkyl) and O, and may further contain 1 to 2 ring members independently selected from >C=O and >S(=O) r (r=0, 1 or 2), with the proviso that NN, NO and NS (=O) are not included between the members of said non-aromatic ring. r=1,2 There are no heteroatom-heteroatom bonds other than the aromatic ring is selected from a 5-membered monocyclic ring containing one ring member selected from NH, N, O and S, which may further contain 1 to 2 N ring members, and a 6-membered monocyclic ring containing 0, 1 or 2 N ring members; the bicyclic ring system is optionally substituted by 1 to 4 F; 1 to 4 C optionally substituted by 1 to 3 F 1-3 - optionally substituted by alkyl, Cl, -CN, -CONH2, -CONH(C 1-4 -alkyl), -CON(C 1-4 -alkyl)2, -COOH, -COO-C 1-4 -Alkyl, HO-C 1-3 -Alkylene-, C 1-3 -Alkyl-OC 1-3 -Alkylene-, C 1-3 -Alkyl-CO-NH-, C 1-3 -Alkyl-S(=O)2-NH-, OH and C 1-3 -alkyl-O- (optionally substituted with 1 to 3 F).

[0077] According to another embodiment, R 3 and R 4 is R 3 and R 4 together with the amide N atom to which they are attached form a fused 8- to 10-membered bicyclic ring system; R 3 / 4 - selected from the G2c group, the bicyclic ring system is a heterocyclyl or heteroaryl consisting of one non-aromatic and one aromatic ring, and phenyl and pyridine; the non-aromatic ring contains the amide N atom and may contain one ring member selected from =N-, >N- and O; the aromatic ring is selected from a 5-membered monocyclic ring containing one ring member selected from N, NH, O, and S, and optionally containing one further ring member N; the bicyclic ring system is optionally substituted by 1-2 F; 1 to 2 C optionally substituted by 1 to 3 F 1-2 - optionally substituted by alkyl, Cl and C 1-2 -alkyl-O- (optionally substituted with 1 to 3 F).

[0078] According to another embodiment, R 3 and R 4 is R 3 and R 4 together with the amide N atom to which they are attached form an 8-9 membered fused bicyclic heteroaryl; R 3 / 4 - selected from the group G3c, The heteroaryl may contain one non-aromatic ring containing the amide N atom, and may contain one ring member >N- that is not adjacent to the amide N atom. and one pyrazolo or imidazolo ring It consists of: The heteroaryl may be substituted with 1 to 2 CH3.

[0079] According to another embodiment, R 3 and R 4 is R 3 and R 4 together with the amide N atom to which they are attached form a heteroaryl [ka] Forming R 3 / 4 -G4c group.

[0080] Stereochemistry: According to one embodiment, the stereochemistry of the compound of formula (I.0) is that of formula (I.1) [ka] This is due to.

[0081] According to another embodiment, the stereochemistry of the compound of formula (I.0) is that of formula (I.2): [ka] This is due to.

[0082] Further preferred subembodiments of the compounds of formula (I.0) are set forth as embodiments (Ia) to (Iz) in Table 1 below, where the above definitions of the substituents are used. For example, in column R 1 and item R in row (Ia) 1 -G1 in embodiment (Ia) is a substituent R 1 But R 1 -G1 means selected from the definitions indicated. The same applies to other variables incorporated in the general formula as well.

[0083] [Table 1]

[0084] R 1 , R 2 , R 3 , R 4 With regard to the definition of and n, the subembodiments (Ia) to (Iz), in particular (Iw) to (Iz), which correspond to the subembodiments (Ia) to (Iz) of Table 1, are particularly preferred, the stereochemistry of which compounds is according to formula (I.1), i.e. the embodiments (I.1-w), (I.1-x), (I.1-y) and (I.1-z). Particularly preferred compounds, their salts, or any solvates or hydrates thereof, are those described in the Examples section and in the Experimental Data.

[0085] According to one embodiment, the compound of formula (I.0) is selected from the group consisting of: [Table 2] JPEG2024099528000040.jpg232170 JPEG2024099528000041.jpg222163 JPEG2024099528000042.jpg229163 JPEG2024099528000043.jpg229163 JPEG2024099528000044.jpg180163

[0086] According to another embodiment, the compounds of formula (I.0) and / or (I.1) are selected from the group consisting of: [Table 3] JPEG2024099528000046.jpg188166

[0087] According to another embodiment, the compounds of formula (I.0) and / or (I.1) are selected from the group consisting of: [Table 4] JPEG2024099528000048.jpg228165 JPEG2024099528000049.jpg92165

[0088] According to another embodiment, the compounds of formula (I.0) and / or (I.1) are selected from the group consisting of: [Table 5] JPEG2024099528000051.jpg232165

[0089] According to another embodiment, the compounds of formula (I.0) and / or (I.1) are selected from the group consisting of: [Table 6]

[0090] According to another embodiment, the compounds of formula (I.0) and / or (I.1) are selected from the group consisting of: [Table 7]

[0091] According to another embodiment, the compounds of formula (I.0) and / or (I.1) are selected from the group consisting of: [Table 8] JPEG2024099528000055.jpg185165

[0092] According to another embodiment, the compound of formula (I.0) and / or (I.1) is: [Table 9]

[0093] According to another embodiment, the compounds of formula (I.0) and / or (I.1) are selected from the group consisting of: [Table 10]

[0094] According to another embodiment, the compounds of formula (I.0) and / or (I.1) are selected from the group consisting of: [Table 11]

[0095] preparation The compounds according to the invention and intermediates thereof can be obtained using synthetic methods known to those skilled in the art and described in the organic chemistry literature, for example in standard textbooks, monographs and reviews covering the basic, applied and technical subjects of organic chemistry, especially organic synthesis. Preferably, the compounds are obtained similarly to the preparation methods described more fully hereafter in the present specification, particularly in the experimental section. In some cases, the sequence adopted in carrying out the reaction schemes can be varied. Variants of these reactions known to those skilled in the art but not described in detail herein may also be used. General methods for preparing the compounds according to the invention will be clear to those skilled in the art upon review of the schemes that follow. The starting compounds are commercially available or can be prepared by methods described in the literature or herein, or can be prepared in a similar or similar manner. Before carrying out the reaction, any corresponding functional groups in the starting compounds can be protected using conventional protecting groups. These protecting groups can be cleaved again at a suitable stage in the reaction sequence, using methods familiar to those skilled in the art and described in the literature covering the use of protecting groups in organic synthesis.

[0096] Scheme 1: [ka] Scheme 1: Compounds of formula (I), such as (I.0), (I.1) or (I.2), and compounds of formula (IV) can be reacted with suitable coupling agents (e.g., O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethylpronium-hexafluorophosphate (HATU), ... The respective acids of formula (II) and formula (V) (either the free acid or Li) can be prepared by using (benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate (TBTU), (benzotriazol-1-yloxy)tri-pyrrolidinophosphonium hexafluorophosphate (PyBOP), carbodiimide reagents, and the like, and a base (e.g., triethylamine, N,N-diisopropyl-ethylamine, pyridine, and the like). + , Na + , K + and a suitable amine of formula (III) (either as the free amine or as a salt such as the hydrochloride, hydrobromide, etc.). 1 , R 2 , R 3 , R 4 and n have the meaning defined earlier in the specification. Alternatively, the respective carboxylic acid is converted to the carboxylic acid chloride (e.g., using oxalyl chloride or thionyl chloride in DCM) and coupled directly with the amine (III) in the presence of a suitable base (e.g., triethylamine, N,N-diisopropyl-ethylamine, pyridine, etc.).

[0097] Compounds of formula (IV) have been reported in the literature and may also be obtained in enantiomerically enriched or pure form (see, for example, DE-A-4132763, EP-A-0388789, EP-A-0254245, EP-A-0450504, and Med. Res. Rev. 1989, 9, 181-218).

[0098] Scheme 2: [ka] Scheme 2: Imines (R 1 , R 2 , R 3 , R 4 and n have the meanings defined earlier herein) can be reduced to the corresponding amines (II) and (I), respectively, by using hydrogen in the presence of a transition metal catalyst or a suitable hydride source. Suitable hydride sources include NaBH4, KBH4, Na(NC)BH3, NaHB(OAc)3, Me4NBH4 and Me5NBH4, used in the presence of Lewis or Brönsted acids or transition metals, at low to high temperatures (-70°C to 100°C), in a suitable solvent (e.g., toluene, DCM, THF, MeCN, HO, etc., or mixtures thereof, depending on the hydride source). n Boron hydrides such as Bu4NBH4, alanates such as LiAlH4, L-selectride, HAl i Select rides such as Bu2, pinacolborane, H3B *The catalyst may be THF, boranes such as 9-BBN-H and Et2BH, or silanes such as Et3SiH and Cl3SiH. A more specific experimental protocol, which may be more generally applicable here, includes NaBH4 and an acid, such as aqueous HCl or acetic acid, in 1,2-dichloroethane at 0°C to 40°C. The active catalyst, which may be used in combination with molecular hydrogen, is preferably derived from, for example, Co, Ni, Pd, Pt, Rh, Ru and Ir. The reduction of the imine in the presence of one of these transition metal catalysts, and optionally in the presence of ligands that coordinate to the transition metal and other additives, may be carried out with hydrogen (1 to 200 bar) in a suitable solvent (e.g. DCM, EtOAc, EtOH, THF, etc.) at 0°C to 150°C. Compounds (I) and (II) obtained by this procedure, depending on the reducing agent and conditions applied, are mixtures of diastereomers or pure diastereomers which can be resolved into the individual stereoisomers by methods known to those skilled in the art to obtain the pure stereoisomers, e.g. (I.1) or (I.2).

[0099] The reduction of imines (IV) or (V) can also be carried out stereoselectively by using either a chiral hydride or hydrogen in the presence of a chiral catalyst to give compounds (I) or (II) as enriched or pure stereoisomers, depending on the enantiopurity of the starting imine, (IV) or (V), and the conditions used. For example, n The chiral hydride (→ n Bu4NHB((S) or (R)-N-Cbz-proline)3) can be a suitable reagent for the reduction of imines (IV) and (V) with high stereochemical selectivity. The reaction is preferably carried out in DCM at -78°C to 40°C using a chiral hydride formed in a separate step or in situ before the addition of the imine.

[0100] Reduction of the imine can also be carried out using ester (VI) under some of the conditions described above (Scheme 3) to give the corresponding amine, which can be converted to compound (II) by hydrolysis of the ester group as described below (Scheme 3) and then to compound (I) by coupling with amine (III) as further described above (Scheme 1).

[0101] Scheme 3 [ka] R'=C 1-4 -Alkyl or benzyl Scheme 3: Acid of formula (V) (R 1 , R 2 and n has the meaning defined hereinbefore) are preferably prepared from the corresponding ester (VI) by hydrolysis or hydrogenolysis, depending on the nature of R'. Esters of lower alkyl groups, such as ethyl or methyl esters, are preferably cleaved by hydrolysis with hydroxide salts, such as NaOH, LiOH or KOH, in a mixture of water and a suitable miscible solvent, such as THF, MeOH, EtOH, 1,4-dioxane, or mixtures thereof, at ambient or elevated temperature. The acids can be isolated either as salts with metal cations or as carboxylic acids. tert-Butyl esters are preferably cleaved by treatment with an acid, such as hydrochloric acid or TFA, in a suitable solvent, such as DCM, 1,4-dioxane, MeOH, EtOH, THF, water, or mixtures thereof. Benzyl esters are preferably cleaved by hydrogenolysis under a hydrogen atmosphere (preferably 1-5 bar) in a suitable solvent (eg EtOH, MeOH, THF, DCM or EtOAc) with a suitable catalyst (eg palladium on carbon).

[0102] Compounds of formula (V) have been reported in the literature and may also be obtained in enantiomerically enriched or pure form (see, for example, EP-A-0 388 789, EP-A-0 254 245 and DE-A-4 132 763). Scheme 4

[0103] [ka] R'=C 1-4 -Alkyl or benzyl

[0104] Scheme 4: Esters of formula (VI) (R 1 , R 2 and n has the meaning defined earlier in this specification) may be prepared from amides (VII) using a variety of synthetic strategies. A more preferred procedure involves converting the amide group in (VII) to the corresponding imidoyl chloride or phosphate anhydride using diethyl chlorophosphate in the presence of a base (e.g., 1,8-diazabicyclo[5.4.0]undecene (DBU)) in a suitable solvent (e.g., THF, 1,4-dioxane, etc.) at moderate temperatures (preferably between 0° C. and 40° C.). The thus modified acylhydrazine (R 1 Addition of -CO-NHNH2) to such activated amides gives N-acylaminoamidine derivatives which can be converted to triazoles by heating (in some cases up to 140°C).

[0105] Alternatively, the triazoles (VI) can be obtained by applying a three-step procedure via the thioamide of the amide (VII), which is subsequently treated with hydrazine to give the corresponding N-aminoamidine, which is then converted to the appropriate orthoester (R 1 -C(OC 1-2-alkyl)3) to the triazole. This procedure, its variations, and alternative synthetic routes are reported in the organic chemistry literature and known to those skilled in the art (see, for example, EP-A-0388789 and EP-A-0254245).

[0106] Compounds of formula (VI) have been reported in the literature and may be obtained in enantiomerically enriched or pure form (see, for example, European Patent Application Publication No. 0388789). Scheme 5 [ka] R'=C 1-4 -Alkyl or benzyl

[0107] Scheme 5: Esters of formula (VII) (R 2 and n has the meaning defined earlier in this specification) may be prepared from ketone (VIII) in one, two or three separate synthetic steps. A well-established synthesis of compound (VII) is via the N-bromoacetyl derivative of compound (VIII), which can be obtained by treating compound (VIII) with bromoacetyl bromide in the presence of a base (e.g., NaHCO3) in a suitable solvent (e.g., toluene and water) at 0°C to 80°C. This intermediate is then treated with an ammonia source (e.g., aqueous ammonia or ammonia in THF) to displace the bromine and obtain the corresponding N-aminoacetyl derivative. The seven-membered ring is then formed by reacting the amino group with the keto group with the aid of suitable additives in a suitable solvent (e.g., silica gel in toluene, pyridine in HOAc or methanesulfonic acid in 1,4-dioxane) at elevated temperatures (preferably between 30°C to 130°C) to obtain compound (VII).

[0108] This procedure has also been reported in the literature and applied to the synthesis of enantiomerically enriched or pure compounds (see, for example, EP 0254245 and EP 0388789). Compound (VII) can also be obtained in just one reaction step from compound (VIII), as reported in Org. Lett. 2017, 19, 1454-1457.

[0109] Scheme 6 [ka] R'=C 1-4 -Alkyl or benzyl Scheme 6: Compounds of formula (VIII) can be prepared from cyanoketones (IX) and ketones (X) according to the reported protocol for the so-called Gewald reaction; R 2 and n have the meanings defined hereinbefore. Thus, compounds (IX) and (X) are combined and treated with a base (e.g., NEt3, HNEt2, morpholine, piperidine, pyridine, etc.) in the presence of elemental sulfur in a solvent (e.g., MeOH, EtOH, DMF, 1,4-dioxane, etc.) at 0° C. to 120° C.

[0110] Alternatively, this conversion may be carried out in two separate steps, forming a condensation product from compounds (IX) and (X) in a first step (Knoevenagel reaction) and product (VIII) upon treatment with elemental sulfur and a base in a second step. Variations on these procedures have been reported in the organic chemistry literature. Compound (IX) is a known compound or can be prepared in the same manner as the former.The main and specific access routes to enantiomerically enriched or pure compound (X) are also reported in the organic chemistry literature (see, for example, EP0388789, Archiv der Pharmazie 1996, 329, 291-300 and Green Chem. 2017, 19, 5122-5130).

[0111] Scheme 7 [ka] R"=C 1-4 -Alkyl or benzyl

[0112] Scheme 7: Cyanoketones of formula (IX) (R 2 and n have the meanings defined earlier in this specification) can be reacted with the corresponding ester (XI) and deprotonated acetonitrile (NCCH2 - The deprotonated acetonitrile species is preferably prepared from the ester (XI) in a solvent, preferably at −78° C. to 40° C., depending on the base used, in a suitable base (e.g., NaH, LiN i Pr2, LiN(SiMe3)2, KO t Further synthetic routes and procedures for the preparation of compounds of formula (IX) are reported in the organic chemistry literature.

[0113] Scheme 8 [ka] R'=C 1-4 -Alkyl or benzyl; R"=C 1-4 -Alkyl or benzyl

[0114] Scheme 8: Compounds of formula (I) can also be obtained by following the route outlined in Scheme 8; 2 , R 3 , R 4and n have the meanings defined earlier in this specification. The synthetic sequence starts with the Gewald reaction of ketone (X) with cyanoester (XII) to give aminothiophene (XIII) (see experimental part and WO 2008 / 063667 for specific reaction conditions). Aminothiophene (XIII) can be acetylated at N with methoxyacetyl chloride in the presence of a base (e.g. pyridine) in an inert solvent (e.g. DCM) at ambient temperature to give compound (XIV). The methoxy group serves as a masked leaving group, which is intended to be displaced by ammonia to introduce the amino at a later stage of the synthesis. Thus, numerous other masked or protected amino equivalents, such as phenoxy instead of methoxy, can be envisaged for this purpose. Compound (XIV) can then be converted to triazole (XVI) via thioamide (XV). The latter compounds can be obtained by treating (XIV) with Lawesson's reagent (or diphosphorus pentasulfide) in a solvent (e.g., 1,4-dioxane or toluene) at elevated temperatures (60°C-120°C). Triazoles (XVI) can be formed by treating thioamides (XV) with hydrazine in a solvent (e.g., THF or 1,4-dioxane) at ambient temperature to give N-aminoamidine intermediates, which are then reacted with trialkyl orthoacetates (e.g., MeC(OMe)3) or acetamide dialkyl acetals (e.g., MeC(OMe)2(NMe2) at elevated temperatures (about 60°C-120°C), optionally in the presence of an acid (e.g., p-TsOH or MeCOOH). Alternatively, Under similar conditions, acetylhydrazine can be used instead to obtain the triazole. The bromide (XVIII) can be generated from compound (XVI) by direct displacement of the methoxy group with bromide or via the alcohol derivative (XVII), depending on the conditions applied. The route via the alcohol requires cleavage of the methoxy ether (e.g., with BBr3 in DCM) followed by transfer of the hydroxyl group with Br (e.g., MeSO2Br and NEt3 in DCM).Compound (XIX) can then be obtained by treating bromide (XVIII) with ammonia (e.g., in methanol at ambient temperature) and heating the displacement product, optionally in the presence of additional base (e.g., NEt3), to achieve simultaneous cyclization and amide formation. The thioamide in (XX) can be introduced by treating the amide (XIX) with Lawesson's reagent or P2S5 in an inert solvent (e.g., toluene or 1,4-dioxane) at elevated temperature (preferably between 60°C and 120°C). The key steps, ester hydrolysis, described in Scheme 3, and amide formation in Scheme 1 are followed to convert the ester functionality in (XX) to the corresponding amide to give compound (XXII); ester hydrolysis can be achieved using NaOH in a mixture of water and methanol at ambient temperature, while amide formation can be achieved by reacting the desired amine (R 3 R 4 NH) and carbonyldiimidazole. Methylation of sulfur in thioamide (XXII) can be achieved with methyl iodide or methyl trifluoromethanesulfonate in a solvent (e.g., acetone or MeCN) at ambient temperature, optionally in the presence of a base (e.g., KOtBu), to give compound (XXIII), which has a functional group (-N=C(SMe)-) suitable for transition metal catalyzed coupling reaction with aromatic nucleophiles such as boronic acids or zinc halides to attach aromatic residues. Coupling of compound (XXIII) with aromatic boronic acids (RB(OH)2) can be carried out in a solvent (e.g., NMP or 1,4-dioxane) at ambient or elevated temperatures (preferably between 20°C and 120°C) using transition metal catalysts based on Pd (e.g., Pd(PPh3)4) and Cu-based additives (e.g., copper(I) thiophene-2-carboxylate) to give compound (I'), i.e., compound (I) (where R 1 The synthesis scheme outlined in Scheme 8 can be used to obtain 1 The present invention is not limited to compounds having methyl for R as defined earlier in this specification. 1This can in principle be extended to any other residue encompassed by the meaning of

[0115] The compounds of formula (I) may be resolved into their enantiomers and / or diastereomers, as specified below: for example, cis / trans mixtures may be resolved into their cis and trans isomers, diastereomeric mixtures may be separated into their diastereomers and racemates may be separated into their enantiomers.

[0116] Cis / trans mixtures can be resolved into their cis and trans isomers, for example, by chromatography. Compounds of formula (I) occurring as racemates can be separated into their optical antipodes by methods known per se, and diastereomeric mixtures of compounds of general formula (I) can be resolved into their diastereomers by taking advantage of their different physicochemical properties, using methods known per se, for example, chromatography and / or fractional crystallization; if the compounds obtained hereafter are racemic, they can be resolved into their enantiomers as described below.

[0117] The racemates are preferably resolved by column chromatography on chiral phases, or by crystallization from optically active solvents, or by reaction with optically active substances forming salts or derivatives such as esters or amides with the racemates. Salts can be formed with enantiomerically pure acids in the case of basic compounds, and with enantiomerically pure bases in the case of acidic compounds. Diastereomeric derivatives are formed with enantiomerically pure auxiliary compounds, such as acids, their activated derivatives or alcohols. Separation of the diastereomeric mixtures of salts or derivatives thus obtained can be achieved by taking advantage of their various physicochemical properties, such as differences in solubility. The free antipodes can be liberated from the pure diastereomeric salts or derivatives by the action of suitable agents. The optically active acids commonly used for such purposes, and the optically active alcohols applicable as auxiliary residues, are known to those skilled in the art. As noted above, compounds of formula (I), such as (I.0), can be converted to salts, particularly pharma- ceutically acceptable salts, for use in medicines. As used herein, "pharmaceutically acceptable salts" refer to derivatives of the disclosed compounds where the parent compound is modified by making acid or base salts thereof. The compounds according to the invention can also be advantageously obtained using the methods described in the examples that follow, which can also be combined for this purpose using methods known to the skilled person from the literature.

[0118] Pharmacological activity and suitability for pharmaceutical use The activity of the compounds of the invention, and their suitability for pharmaceutical use, can be demonstrated using the following assays: biological methods

[0119] The ability of compounds of formula (I.0) to inhibit activation of the PAF receptor (PAFR) by PAF C-16 ligand (PAF) is determined using the following cellular HTRF IP1 assay (IP1 Gq assay kit from CisbioI, catalog number: 62IP1APEJ) in assay buffer (1×HBSS, 20 mM Hepes, pH 7.4, 50 mM LiCl, and containing 0.1% (w / v) BSA). Assessment of inhibition of PAFR activation using endpoint assays

[0120] HEK293 cells (generated in-house) overexpressing human PAFR are seeded (15,000 cells per well) in poly-D-lysine coated 384-well white cell culture microtiter assay plates with lids. The plates are then incubated overnight at 37° C. / 5% CO2. The next day, the cells are washed and then various concentrations of test compounds (compounds in 100% DMSO; final concentration of DMSO in the wells is 1%) are added to the assay plates by an Echo555 acoustic liquid handler. The plates are then incubated with the lids on for 90 minutes at 37° C. / 5% CO2. After this, PAF ligand (Cayman Chemical Company, article number: 60900) is added at a final concentration of 11 nM. The plates are then incubated with the lids on for 60 minutes at 37° C. / 5% CO2. Then, 5 μl of anti-IP1-antibody-cryptate solution and 5 μL of IP1-d2 solution are added per well to all wells of the plate, and the plate is incubated for another 60 minutes at room temperature protected from light. The emission is measured at 620 nm and 665 nm (excitation wavelength: 320 nm) using an Envision reader (PerkinElmer).

[0121] IC of the compounds according to the invention 50The values ​​are shown in the table below. The compound numbers correspond to the numbers of the examples in the experimental section. When a mixture of isomers with respect to the configuration at C-13 is used in the test, the observed activity can be mainly attributed to the (13S)-isomer, which is the isomer according to the present invention. This is evident from a direct comparison of (reference) Examples 67-71 and 74-78.

[0122] [Table 12]

[0123] Evaluating the inverse agonist mode of action using endpoint assays Due to the constitutive activity of PAFR, the basal HTRF IP1 signal is higher in HEK293 cells overexpressing human PAFR compared to non-transfected HEK293 cells. The ability of test compounds to act as inverse agonists at PAF receptors can be determined using a modified protocol of the cellular HTRF IP1 assay described above. Various concentrations of test compounds are added to assay plates containing HEK293 cells overexpressing human PAFR and incubated for 340 minutes at 37°C / 5% CO2 without the addition of RAF ligand. The inverse agonist effect of test compounds is demonstrated by a reduction in HTRF IP1 signal to the level of non-transfected HEK293 cells. EVALUATION OF THE IN VIVO EFFICACY OF AN ANIMAL MODEL OF LASER-INDUCED CHOROIDAL NEOVASCULARIZATION IN BROWN NORWAY RATS Male Brown Norway rats (BN / Crl) weighing between 160g and 180g are obtained from Charles River Labs (Sulzfeld, Germany). Animals are maintained in group housing with a 12h / 12h light / dark cycle (lights on at 6AM) and allowed to acclimate for one week before the start of the study. Animals have free access to standard chow (Provimi Kliba #3438) and tap water. Animals receive test compounds by oral gavage once daily for two weeks.

[0124] Under anesthesia, on day 1, the animal is placed in front of the fundus camera to position the optic nerve in the center of the image. Laser treatment is performed with a green argon laser (Merilas) at a wavelength of 532 nm using a Micron IV system (Phoenix Research Laboratories, Pleasanton, CA). The diameter of the laser beam is matched to the diameter of the optic nerve, and laser pulses with an energy of 400 mW and a duration of 150 ms are used to generate four lesions per eye. The lesions are placed between the large blood vessels at a distance of approximately twice the diameter of the optic nerve. Successful disruption of Bruch's membrane is recognized by the formation of an air bubble immediately after the laser beam and confirmed by OCT scanning.

[0125] The animals are sacrificed 14 days after the laser treatment by cervical dislocation under anesthesia. The eyes are enucleated and cut along the ora serrata. The cornea, iris, lens, vitreous and retina are removed and the remaining eye cup (consisting of PRE, choroid and sclera) is fixed in PFA (4%) for 1 h at 4°C and then transferred to PBS containing 0.1% Triton X-100 for 1 h at 4°C. The eye cup is stained with FITC-labeled isolectin B4 (10 μg / ml in saline; obtained from Sigma Aldrich, Cat. No. L9381) overnight at room temperature in the dark and washed three times with PBS. The eye cup is transferred to a glass slide and incised four times to form a flattened cloverleaf-like structure. The tissue is covered with mounting medium (Vectashield H-1200 containing DAPI) and a coverslip is placed on top to obtain RPE / choroid / sclera flatmounts (RPE side up). Flatmounts are stored at 4°C in the dark until analysis.

[0126] The samples are analyzed using a LSM700 confocal laser scanning microscope (Carl Zeiss, Jena; gain 650, laser intensity 2%) at a wavelength of 488 nm to obtain images of the lesions. Lesion size measurements are performed using Zen Blue software. The efficacy readout is the lesion size stained by isolectin B4 in RPE-choroid flat mounts. Evaluation of compound binding to melanin

[0127] The ability of compounds to bind to melanin is determined using an in vitro assay using melanin from Sepia officinalis (Sigma-Aldrich, Cat. No. M2649) in assay buffer (phosphate buffer, pH 6.5, 0.9% (w / v) NaCl). To measure binding, a 1 mg / mL (w / v) melanin suspension and a 0.1% (w / v) BSA solution (control buffer) are prepared in assay buffer. Compounds are incubated in microtiter plates at a final compound concentration of 1 μM (compounds in DMSO:assay buffer (40:60) are added to the plate: final DMSO concentration is 1%) with a 1 mg / mL melanin suspension (to determine free compound concentration) and without melanin (to determine total compound concentration) in control buffer. The plate is incubated for 2 hours at 37° C. on an orbital shaker at 900 rpm. After incubation, the plate is centrifuged to pellet the melanin and bound compounds. Supernatants from both melanin and control wells are sampled and concentrations are measured using LC-MS. Bound concentrations are calculated by subtracting free compound concentrations from total compound concentrations.

[0128] Chemical stability evaluation Decomposition studies are used to mimic the chemical stability of compounds in the acidic part of the gastrointestinal tract.The compounds of the present invention show high chemical stability in acidic aqueous media (pH value of about 1.2), which makes the application of the compounds of the present invention as medicines for treating human diseases less restrictive and problematic.

[0129] The chemical stability of the compounds of the present invention at pH values ​​of about 1.2 is determined as follows: The compound is dissolved in a mixture of acetonitrile / 0.1 M aqueous HCl (ratio: 2:3; pH approx. 1.2) in an HPLC vial to obtain a concentration of approximately 0.25 mg / ml. The vial is then transferred to an HPLC autosampler system and maintained at a temperature of 37° C. The first sample is taken and immediately injected into a standard HPLC system equipped with a UV DAD detector. A further sample is injected after 24 hours. The amount of decomposed compound is measured by determining the recovery [%] of the compound during the 24 hours of injection using an HPLC standard gradient method: the peak area of ​​the main peak for the first injection (AUt0) is determined and set as 100%. The peak area of ​​the main peak is also determined for the 24 hours of injection (AUt0). 24h ), (AU 24h ) / AU t0 ) [%]. The chemical stability of the exemplary compounds according to the invention was tested as described above, and for all of them, the amount of compound decomposed was found to be at most 3% or less.

[0130] The following table shows the degree of decomposition of representative compounds of the present invention. The numbers of each compound correspond to the numbers of the examples in the experimental section. [Table 13]

[0131] Permeability assessment Caco-2 cells (1~2×10 5 Cells / 1cm 2 The cells (area 100 x 100 mm) are seeded onto filter inserts (Costar transwell polycarbonate or PET filters, 0.4 μm pore size) and cultured (in DMEM) for 10 to 25 days. Compounds are dissolved in an appropriate solvent (1-20 mM stock solution, such as DMSO). Stock solutions are diluted with HTP-4 buffer (128.13 mM NaCl, 5.36 mM KCl, 1 mM MgSO4, 1.8 mM CaCl2, 4.17 mM NaHCO3, 1.19 mM Na2HPO4 x 7H2O, 0.41 mM NaH2PO4 x H2O, 15 mM HEPES, 20 mM glucose, pH 7.2) to prepare transport solutions (0.1-300 μM compound, final DMSO <= 0.5%). Transport solutions (TL) are applied to the apical or basolateral donor side to measure AB or BA permeability, respectively (three filter replicates). The receiver side contains HTP-4 buffer supplemented with 2% BSA. Samples are taken from the donor side as well as from the receiver side at the beginning and end of the experiment and at various time intervals up to 2 hours for concentration determination by HPLC-MS / MS or scintillation counting. The sampled receiver volume is replaced with fresh receiver solution.

[0132] Assessment of metabolic stability in human or rat liver microsomes Metabolic degradation of test compounds is assayed using pooled human or rat liver microsomes at 37° C. Final incubation volumes of 100 μl per time point contain TRIS buffer (pH 7.6) (0.1 M), magnesium chloride (5 mM), microsomal protein (1 mg / mL) and test compound at a final concentration of 1 μM at room temperature. After a short preincubation period at 37°C, the reaction is initiated by the addition of reduced beta-nicotinamide adenine dinucleotide phosphate (NADPH, 1 mM) and terminated after various time points by transferring aliquots to solvent. In addition, NADPH-independent degradation is monitored in NADPH-free incubations and terminated at the final time point. The quenched incubations are pelleted by centrifugation (10000g, 5 min). An aliquot of the supernatant is assayed by LC-MS / MS for the amount of parent compound. The half-life (t1 / 2 INVITRO) is determined by the slope of a semi-log plot of the concentration-time profile.

[0133] Assessment of metabolic stability in human or rat hepatocytes The metabolic degradation of the test compound is assayed in a hepatocyte suspension. Hepatocytes (usually cryopreserved) are incubated in an appropriate buffer system (e.g., Dulbecco's modified Eagle's medium, plus 3.5 μg glucagon / 500 mL, 2.5 mg insulin / 500 mL, and 3.75 mg hydrocortisone / 500 mL) containing 5% serum species. After 30 min (typically) pre-incubation in an incubator (37 °C, 10% CO), add 5 µL of test compound solution (80 µM; from 2 mM in DMSO stock solution diluted 1:25 with culture medium) to 395 µL of hepatocyte suspension (cell density ranging from 0.25 to 5 myocytes / mL, typically 1 myocyte / mL; final concentration of test compound 1 µM, final DMSO concentration 0.05%). Cells are incubated (incubator, orbital shaker) for 6 hours and samples (25 μL) are taken at 0, 0.5, 1, 2, 4 and 6 hours. Samples are transferred to ACN and pelleted by centrifugation (5 min). Supernatants are transferred to a new 96 deep-well plate, solvent evaporated under nitrogen and resuspended. The loss of parent compound is analyzed by HPLC-MS / MS. CLint is calculated as follows: CL_INTRINSIC=dose / AUC=(C0 / CD) / (AUD+clast / k)×10 / 60. C0: initial concentration in incubation [μM], CD: cell density of viable cells [10e6 cells / mL], AUD: area under data [μM×h], clast: concentration of last data point [μM], k: slope of regression line for loss of parent [h-1].

[0134] Assessment of plasma protein binding This equilibrium dialysis (ED) technique is used to determine the approximate in vitro binding rate of test compounds to plasma proteins. Dianorm Teflon dialysis cells (micro 0.2) are used. Each cell consists of a donor and an acceptor chamber separated by an ultrathin semipermeable membrane with a molecular weight cut-off of 5 kDa. Stock solutions of each test compound are prepared at 1 mM in DMSO and diluted to a final concentration of 1.0 μM. The following dialysis solutions are prepared in pooled human or rat plasma (containing NaEDTA) from male and female donors. A 200 μL aliquot of dialysis buffer (100 mM potassium phosphate, pH 7.4) is dispensed into the buffer chamber. A 200 μL aliquot of the dialysis solution of the test compound is dispensed into the plasma chamber. Incubation is performed for 2 hours at 37° C. under rotation.

[0135] At the end of the dialysis period, the dialysate is transferred to a reaction tube. The tube for the buffer fraction contains 0.2 mL of ACN / water (80 / 20). A 25 μL aliquot of the plasma dialysate is transferred to a deep well plate and mixed with 25 μL of ACN / water (80 / 20), 25 μL of buffer, 25 μL of calibration solution and 25 μL of internal standard solution. Protein precipitation is performed by adding 200 μL of ACN.

[0136] A 50 μL aliquot of the buffered dialysate is transferred to a deep well plate and mixed with 25 μL blank plasma, 25 μL internal standard solution and 200 μL ACN. The samples are run on an HPLC-MS / MS system and evaluated with Analyst software. The percent binding is calculated using the following formula: % binding = (plasma concentration - buffer concentration / plasma concentration) x 10

[0137] Solubility evaluation The aqueous solubility of the test compound is determined by comparing the amount dissolved in the buffer with the amount in ACN / water (1 / 1) solution. Starting with a 10 mM DMSO stock solution, an aliquot is diluted with ACN / water (1 / 1) or buffer, respectively. After shaking for 24 hours, the solution is filtered and analyzed by LC-UV. The amount dissolved in the buffer is compared with the amount in the ACN solution. Solubility is typically measured as 0.001-0.125 mg / mL at a DMSO concentration of 2.5%. If the compound is more than 90% soluble in the buffer, this value is noted with a ">".

[0138] The compounds of the invention also demonstrate favorable solubility at low pH values ​​(pH 2.2 mimics the acidic portion of the gastrointestinal tract), a desirable feature for drug development and administration purposes. The following table shows data for selected compounds of the invention. [Table 14]

[0139] Evaluation of pharmacokinetic characteristics in rodents Test compounds are administered either intravenously to fed rats or orally to fasted rats. At several time points following administration of the test compound, blood samples are taken, anticoagulated and centrifuged. Analyte concentrations, i.e., administered compound and / or metabolites, are quantified in plasma samples by LC-MS / MS. To determine renal clearance, urine samples are collected over 24 hours after intravenous administration and urinary concentrations of administered compound are quantified by LC-MS / MS. PK parameters are calculated using noncompartmental PK analysis (NCA). The trapezoidal rule is applied (lin up-log down) and the area under 0-tz ) to calculate the area under the individual curves. AUC 0-Inf is the terminal phase extrapolated, and the AUC tz-∞ AUC 0-tz The individual CL values ​​are calculated according to Equation 1.

[0140]

number

[0141] In the second step, the drug-specific renal clearance for each animal is calculated using Equation 2.

number

[0142] Treatment Method In another aspect of the present invention, the compounds of formula (I.0) or pharma- ceutically acceptable salts thereof have suitable properties for use in therapy, i.e., as medicines. In particular, the compounds of formula (I.0) or pharma-ceutically acceptable salts thereof, as well as pharmaceutical compositions containing them, may be useful in treating diseases or conditions in patients that can be affected by antagonizing the platelet-activating factor receptor (PAFR), e.g., that are mediated by undesirable activity of PAFR or in which antagonism of PAFR is beneficial. Further benefits may come from inverse agonism of PAFR. Diseases and conditions that can be affected by antagonizing and / or inverse agonizing PAFR, for example, mediated by undesirable activity of PAFR or for which antagonism and / or inverse agonism of PAFR activity would be beneficial, include ophthalmic disease, cardiovascular disease, cancer, neurological and neurodegenerative disorders, renal disorders, liver disease, and allergies. These disorders include, but are not limited to, retinopathy or diabetic retinopathy, proliferative and non-proliferative retinopathies, diabetic macular ischemia (DMI), geographic atrophy, Stargardt's disease, retinal degeneration in glaucoma, myopic macular degeneration, chronic panuveitis, retinitis pigmentosa, retinal vein occlusion (such as central, bifurcation, or hemiretinal vein occlusion), diabetic macular edema (DME), clinically significant macular edema (CSME), cystoid macular edema (CM), and other conditions that may be associated with glaucoma, including glaucoma, glaucoma, and glaucoma. E), post-lens extraction CME, cryotherapy-induced CME, uveitis-induced CME, endophthalmitis, post-vascular occlusion CME (e.g., central retinal vein occlusion, branch retinal vein occlusion, or hemiretinal vein occlusion), retinal edema, cataract surgery-related complications in diabetic retinopathy, hypertensive retinopathy, retinal trauma, dry and exudative age-related macular degeneration (AMD), polypoidal choroidal vasculopathy (PCV), choroidal neovascularization (CNV;nonexudative choroidal neovascularization), subretinal fibrosis (e.g. associated with nonexudative or exudative choroidal neovascularization), posterior vitreous detachment (PVD), ischemia-reperfusion injury in all kinds of situations, e.g. associated with tissue and / or organ transplantation, surgery-induced brain injury, focal cerebral ischemia, global cerebral ischemia, glioma-associated edema, spinal cord injury, pain, ischemia, focal cerebral ischemia, neurological deficits and agnosia, deep vein thrombosis, stroke, myocardial infarction, atherosclerosis, acquired angioedema, hereditary angioedema (HAE), drug-related (ACE inhibitor) edema, high altitude cerebral edema, cytotoxic cerebral edema, penetrative cerebral Edema, obstructive hydrocephalus, radiation-induced edema, lymphedema, traumatic brain injury, hemorrhagic stroke (e.g. cerebral or subarachnoid stroke), intracerebral hemorrhage, hemorrhagic transformation of ischemic stroke, brain trauma related to injury or surgery, encephalomyelitis, amyotrophic lateral sclerosis, neuropathic pain, cerebral aneurysm, arteriovenous malformation, reduction of blood loss during surgery (e.g. cardiothoracic surgery such as cardiopulmonary bypass or coronary artery bypass graft), blood clotting disorders such as thrombosis, eczema, disorders with an inflammatory component (such as multiple sclerosis), epilepsy, encephalitis, Alzheimer's disease, excessive daytime sleepiness, essential hypertension, diabetes or hyperlipidemia-related elevated blood pressure, renal failure, renal impairment (including chronic kidney disease), interstitial cystitis / bladder pain syndrome, heart failure, microalbuminuria, albuminuria, proteinuria, disorders associated with increased vascular permeability (e.g., increased retinal vascular permeability, increased vascular permeability of the legs, feet, and ankles), intracerebral hemorrhage, deep vein thrombosis, coagulation resulting from fibrinolytic procedures, angina pectoris, angioedema, sepsis, arthritis (e.g., rheumatoid arthritis, osteoarthritis, infectious arthritis), ulcerative colitis, pancreatitis, lupus, gout, psoriasis, inflammatory bowel disease, diabetes, diabetic complications, and metabolic syndrome Comorbid conditions, non-alcoholic steatohepatitis (NASH), allergies, bacterial and viral infections (including HIV infection), anaphylaxis, sepsis, chronic obstructive pulmonary disease (COPD), asthma, periodontitis, psoriasis, urticaria, UVB-induced dermatitis, astrocyte activation-related diseases (e.g. Alzheimer's disease or multiple sclerosis), Parkinson's disease, amyotrophic lateral sclerosis, Creutzfeldt-Jakob disease, stroke, epilepsy and trauma (e.g. brain trauma), allergic edema, e.g. airway obstruction in chronic allergic sinusitis or perennial rhinitis; airway obstruction in acute asthma;These include serositis associated with systemic lupus erythematosus (SLE), acute respiratory distress syndrome (ARDS), cancer (such as breast cancer, colon cancer, esophageal cancer, lung cancer, liver cancer, pancreatic cancer, skin cancer (including melanoma), and cervical cancer), and other diseases;

[0143] Thus, the compounds and pharmaceutical compositions according to the invention are particularly suitable for the treatment of ocular diseases, including diabetic retinopathy, proliferative and non-proliferative retinopathy, diabetic macular edema (DME), retinal vein occlusion, dry and exudative age-related macular degeneration (AMD), geographic atrophy, polypoidal choroidal vasculopathy (PCV) and choroidal neovascularization (CNV; e.g., non-exudative choroidal neovascularization). Furthermore, the compounds and pharmaceutical compositions according to the invention are particularly suitable for the treatment of allergy and inflammation related conditions and diseases, such as urticaria and NASH.

[0144] The compounds and pharmaceutical compositions according to the invention are most particularly suitable for the treatment of diabetic macular edema (DME), dry and exudative age-related macular degeneration (AMD), geographic atrophy, nonexudative choroidal neovascularization (CNV), urticaria and NASH. The applicable daily dose range of the compound of formula (I.0) is usually 0.01 mg to 10 mg per kg of body weight. The actual therapeutically effective amount or therapeutic dosage will, of course, depend on factors known by those skilled in the art, such as the age and weight of the patient, the route of administration and the severity of the disease. In any case, the compound or composition will be administered in a dosage and manner capable of delivering a therapeutically effective amount based on the patient's unique condition.

[0145] The compound and composition, including any combination with one or more additional therapeutic agents according to the present invention, can be administered by oral, intravitreal, transdermal, inhalation, parenteral or sublingual route.Among possible administration methods, oral and intravitreal administration, especially oral administration, are preferred.For intravitreal injection, the preferred dose should not exceed 5mg per eye. The patient to be treated is preferably a mammal, most preferably a human patient. Thus, in another aspect, the present invention provides compounds of formula (I.0), including pharma- ceutically acceptable salts thereof, for use as pharmaceuticals.

[0146] In another aspect, the present invention provides a method of treating a disease or condition mediated by unwanted activity of the platelet activating factor receptor or in which antagonism of the platelet activating factor receptor is beneficial in a patient in need thereof. Similarly, the invention provides a compound of formula (I.0) or a pharma- ceutically acceptable salt thereof for use in a method of treating a disease or condition mediated by undesirable activity of the platelet activating factor receptor, or in which antagonism of the platelet activating factor receptor is beneficial, in a patient in need thereof. Similarly, the invention provides the use of a compound of formula (I.0) or a pharma- ceutically acceptable salt thereof in the manufacture of a medicament for use in a method of treating, in a patient in need thereof, a disease or condition mediated by undesirable activity of the platelet activating factor receptor, or in which antagonism of the platelet activating factor receptor is beneficial. Similarly, the invention provides the use of a compound of formula (I.0) or a pharma- ceutically acceptable salt thereof in a method for treating a disease or condition, in a patient in need thereof, that is mediated by undesirable activity of the platelet activating factor receptor, or in which antagonism of the platelet activating factor receptor is beneficial.

[0147] According to one embodiment, the method of treatment comprises administering to the patient one or more compounds of formula (I.0), or a pharma- ceutically acceptable salt thereof, preferably administering to the patient a therapeutically effective amount of one or more compounds of formula (I.0), or a pharma- ceutically acceptable salt thereof. According to another embodiment, the method of treatment comprises the step of administering to a patient a pharmaceutical composition according to the invention. According to one embodiment, the disease or condition mediated by unwanted activity of the platelet activating factor receptor or in which antagonism of the platelet activating factor receptor is beneficial is selected from ocular indications such as diabetic retinopathy, proliferative and non-proliferative retinopathy, diabetic macular edema (DME), retinal vein occlusion, dry and exudative age-related macular degeneration (AMD), geographic atrophy, polypoidal choroidal vasculopathy (PCV) and choroidal neovascularization (CNV). According to another embodiment, the disease or condition mediated by unwanted activity of the platelet activating factor receptor or in which antagonism of the platelet activating factor receptor is beneficial is selected from allergy- and inflammation-related conditions and diseases, such as hives and NASH. According to another embodiment, the disease or condition mediated by undesirable activity of the platelet activating factor receptor or in which antagonism of the platelet activating factor receptor is beneficial is selected from diabetic complications associated with diabetic retinopathy, such as diabetic macular edema, diabetic macular ischemia and proliferative diabetic retinopathy. According to one embodiment, the patient is a human patient.

[0148] Pharmaceutical Compositions In another aspect of the invention, it is stated that the compounds of the invention, or pharma- ceutically acceptable salts thereof, may be used as the active ingredient in pharmaceutical compositions. Suitable preparations for administering the compounds of the present invention, which may be combined with one or more additional therapeutic agents, will be apparent to those skilled in the art and include, for example, tablets, pills, capsules, suppositories, lozenges, troches, solutions, syrups, elixirs, sachets, injections, inhalants and powders. Oral preparations, particularly solid forms such as tablets or capsules, are preferred. For intravitreal injection, solutions are preferred. The content of the pharmacoactive compound is advantageously in the range of 0.1-90% by weight, for example 1-70% by weight, of the composition as a whole.

[0149] Suitable tablets can be obtained, for example, by mixing one or more compounds according to formula (I.0) with known excipients, such as inert diluents, carriers, disintegrants, adjuvants, surfactants, binders and / or lubricants. The tablets may also consist of several layers. The specific excipients, carriers and / or diluents suitable for the desired preparation will be familiar to the skilled person on the basis of the expert's knowledge. Preference is given to those suitable for the particular formulation and the desired method of administration. The preparations or formulations according to the invention can be prepared using methods known per se, with which the skilled person is familiar, such as, for example, by mixing or combining at least one compound according to formula (I.0) according to the invention or a pharma- ceutically acceptable salt of such a compound with one or more excipients, carriers and / or diluents. Thus, according to another aspect of the present invention there is provided a pharmaceutical composition comprising one or more compounds of formula (I.0), or a pharma- ceutically acceptable salt thereof, optionally together with one or more inert carriers and / or diluents.

[0150] Similarly, pharmaceutical compositions comprising one or more of the above compounds, or pharma- ceutically acceptable salts thereof, optionally together with one or more inert carriers and / or diluents, are provided for use in methods of treating diseases or conditions mediated by undesirable activity of PAFR or in which antagonism of PAFR is beneficial in a patient in need thereof. In particular, the present invention provides pharmaceutical compositions according to the present invention for use in methods of treating ophthalmic indications such as diabetic retinopathy, proliferative and non-proliferative retinopathy, diabetic macular edema (DME), retinal vein occlusion, dry and exudative age-related macular degeneration (AMD), geographic atrophy, polypoidal choroidal vasculopathy (PCV) and choroidal neovascularization (CNV; e.g., non-exudative choroidal neovascularization), as well as allergy- and inflammation-related conditions and diseases such as urticaria and NASH. Furthermore, the present invention relates to the use of a pharmaceutical composition according to the present invention for treating a disease or condition mediated by unwanted activity of PAFR in a patient, preferably a human. Similarly, the present invention relates to the use of a pharmaceutical composition according to the invention for the treatment of a disease or condition in a patient, preferably a human, in which antagonism of PAFR is beneficial.

[0151] According to one embodiment, there is provided a pharmaceutical composition comprising one or more compounds of formula (I.0) or a pharma- ceutically acceptable salt thereof, and one or more additional therapeutic agents, optionally together with one or more inert carriers and / or diluents. For example, the composition comprises one compound of formula (I.0), or a pharma- ceutically acceptable salt thereof, and one or more additional therapeutic agents.

[0152] Combination therapy The compounds of the present invention may further be combined with one or more, preferably one, additional therapeutic agent. According to one embodiment, the additional therapeutic agent is selected from the group of therapeutic agents useful for the treatment of diseases or conditions described herein earlier, in particular ocular diseases such as diabetic macular edema (DME), dry and exudative age-related macular degeneration (AMD), geographic atrophy, nonexudative choroidal neovascularization (CNV), urticaria and NASH, allergy and inflammation related conditions and diseases, or metabolic diseases or conditions such as diabetes, obesity, diabetic complications, hypertension and hyperlipidemia. Additional therapeutic agents suitable for such combinations include in particular those which, for example, enhance the therapeutic effect of one or more active substances for one of the mentioned indications and / or allow for a reduction in the dosage of one or more active substances. Thus, the compounds of the present invention may be combined with one or more additional therapeutic agents selected from the group consisting of antidiabetic agents, agents for the treatment of overweight and / or obesity, agents for the treatment of hypertension, heart failure and / or atherosclerosis, agents for the treatment of eye diseases, and agents for the treatment of conditions and diseases related to allergy and inflammation.

[0153] Antidiabetic agents are, for example, metformin, sulfonylureas, nateglinide, repaglinide, thiazolidinediones, PPAR-(alpha, gamma or alpha / gamma) agonists or modulators, alpha-glucosidase inhibitors, DPPIV inhibitors, SGLT2 inhibitors, insulin and insulin analogues, GLP-1 and GLP-1 analogues, or amylin and amylin analogues, dual agonists containing GLP-1 activity together with glucagon or GIP activity, cycloset, 11β-HSD inhibitors. Other suitable combination partners are, for example, inhibitors of protein tyrosine phosphatase 1, such as glucose-6-phosphatase or fructose-1,6-bisphosphatase, inhibitors of glycogen phosphorylase, glucagon receptor antagonists, and inhibitors of phosphoenolpyruvate carboxykinase, glycogen synthase kinase or pyruvate dehydrokinase, alpha 2-antagonists, CCR-2 antagonists or glucokinase activators, which are substances that affect the deregulation of glucose production in the liver. One or more lipid lowering agents are also suitable as combination partners, such as, for example, HMG-CoA-reductase inhibitors, fibrates, nicotinic acid and their derivatives, cholesterol absorption inhibitors such as PPAR-(alpha, gamma or alpha / gamma) agonists or modulators, PPAR-delta agonists, ACAT inhibitors or bile acid binding substances such as inhibitors of the ileal bile acid transporter, MTP inhibitors or HDL-raising compounds such as CETP inhibitors or ABC1 regulators.

[0154] Therapeutic agents for treating overweight and / or obesity are, for example, antagonists of the cannabinoid 1 receptor, MCH-1 receptor antagonists, MC4 receptor agonists, NPY5 or NPY2 antagonists, β3-agonists, leptin or leptin mimetics, agonists of the 5HT2c receptor, dual agonists of the GLP-1 and glucagon receptors.

[0155] Therapeutic agents for the treatment of hypertension, chronic heart failure and / or atherosclerosis are, for example, A-II antagonists or ACE inhibitors, ECE inhibitors, diuretics, β-blockers, Ca-antagonists, centrally acting antihypertensives, antagonists of alpha-2-adrenergic receptors, inhibitors of neutral endopeptidase, platelet activity inhibitors, etc., or combinations thereof, are preferred. Angiotensin II receptor antagonists are preferably used for the treatment or prevention of hypertension, and diabetic complications, often combined with diuretics such as hydrochlorothiazide.

[0156] Therapeutic agents for the treatment of ocular diseases can include, for example, intravitreally administered corticosteroids, intravitreally administered anti-VEGF therapy, anti-Ang2 inhibitors, dual anti-VEGF / anti-Ang2 inhibitors, anti-PDGF, dual anti-VEGF / anti-PDGF, VAP-1 (AOC3) inhibitors, complement inhibitors (e.g., complement factor 3, 5, B and D inhibitors), bradykinin receptor 1 antagonists, CCR-2 antagonists, PKK inhibitors. Additional treatments for eye diseases can include laser coagulation therapy. Therapeutic agents for treating hives can include, for example, antihistamines, steroids such as cortisone, epinephrine, antibodies to immunoglobulin E, immunosuppressants such as cyclosporin A, and leukotriene receptor antagonists.

[0157] Therapeutic agents for treating NASH include, for example, FXR agonists, FXR / TGR5 agonists, THR-β agonists, ACC inhibitors, TGF-b1 antagonists, LTA4 hydrolase inhibitors, SGLT inhibitors, activin type 2 receptor antagonists, NLRP3 inhibitors, avβ1 integrin inhibitors, cGAS / STING inhibitors, GLP-1R agonists, FGF21 agonists, GLP-1 / glucagon receptor dual agonists, GLP-1 / GIP receptor dual agonists, GLP-1 / FGF21 receptor dual agonists, GLP-1 / GIP / glucagon receptor triple agonists, and the like. The therapeutic agents can include, for example, sGC inhibitors, AOC3 inhibitors, JNK1 inhibitors, CCR2 / 5 inhibitors, ACC inhibitors, DGAT inhibitors, KHK inhibitors, PPARα / δ agonists, FGF19 agonists, β-Klotho / FGFR1c agonists, PNPLA3 inhibitors, NLRP3 inhibitors, THR-β agonists, HSD17β13 inhibitors, galectin-3 inhibitors, SCD1 inhibitors, ASK1 inhibitors, endothelin receptor A antagonists, FASN inhibitors, calpain inhibitors, autotaxin inhibitors, TREM2 agonists, sGC inhibitors, PKK inhibitors, RORc inhibitors, TLR4 inhibitors, and IL11 inhibitors.

[0158] The compounds of the invention and / or pharmaceutical compositions comprising the compounds of the invention, optionally in combination with one or more additional therapeutic agents, may be administered in conjunction with exercise and / or diet. Dosages for the above combination partners are usually from 1 / 5 of the lowest recommended dose to 1 / 1 of the recommended dose. The use of the compounds according to the invention in combination with an additional therapeutic agent may be carried out simultaneously or at staggered times.

[0159] Both the compound according to the invention and the one or more additional therapeutic agents may be present together in one formulation, e.g. a tablet or capsule, or separately in two identical or different formulations, e.g. as a so-called kit of parts. Thus, according to another aspect, the present invention relates to a pharmaceutical composition comprising one or more compounds according to the invention and one or more additional therapeutic agents as described hereinbefore and hereinafter, optionally together with one or more inert carriers and / or diluents. According to another aspect, the present invention provides a method of treating a disease or condition mediated by undesirable activity of the platelet activating factor receptor or in which antagonism of PAFR is beneficial, in a patient in need thereof, comprising the steps of administering to the patient one or more compounds of formula (I.0), or a pharma- ceutically acceptable salt thereof, in combination with one or more additional therapeutic agents as described hereinbefore and hereinafter; Preferably, methods are provided which comprise administering to a patient a therapeutically effective amount of one or more compounds of formula (I.0), or a pharma- ceutically acceptable salt thereof, in combination with a therapeutically effective amount of one or more additional therapeutic agents as described hereinbefore and hereinafter. Similarly, the present invention provides a compound of formula (I.0) or a pharma- ceutically acceptable salt thereof, in combination with one or more additional therapeutic agents described hereinbefore or hereinafter, for use in a method of treating a disease or condition in a patient in need thereof that is mediated by undesirable activity of PAFR, or in which antagonism of PAFR is beneficial. Similarly, the invention provides the use of a compound of formula (I.0) or a pharma- ceutically acceptable salt thereof in the manufacture of a medicament for use in a method of treating a disease or condition, in a patient in need thereof, that is mediated by undesirable activity of PAFR or in which antagonism of PAFR is beneficial, in combination with one or more additional therapeutic agents as described hereinbefore or hereinafter. Similarly, the invention provides the use of a compound of formula (I.0) or a pharma- ceutically acceptable salt thereof in combination with one or more additional therapeutic agents described hereinbefore or hereinafter in a method for treating a disease or condition in a patient in need thereof that is mediated by undesirable activity of PAFR or in which antagonism of PAFR is beneficial.

[0160] According to one embodiment, the method of treatment comprises the steps of administering to a patient one or more compounds of formula (I.0), or a pharma- ceutically acceptable salt thereof, in combination with one or more additional therapeutic agents described hereinbefore and hereinafter; Preferably, the method comprises administering to the patient a therapeutically effective amount of one or more compounds of formula (I.0), or a pharma- ceutically acceptable salt thereof, in combination with a therapeutically effective amount of one or more additional therapeutic agents described hereinbefore and hereinafter.

[0161] According to another embodiment, the method of treatment comprises the step of administering to a patient a pharmaceutical composition comprising one or more compounds according to the invention and one or more additional therapeutic agents as described hereinbefore and hereinafter, optionally together with one or more inert carriers and / or diluents. According to one embodiment, the one or more additional therapeutic agents are selected from antidiabetic agents, agents for the treatment of overweight and / or obesity, agents for the treatment of hypertension, heart failure and / or atherosclerosis, and agents for the treatment of eye diseases, in particular from such agents specifically mentioned above.

[0162] According to one embodiment, the disease or condition mediated by undesirable activity of PAFR or in which antagonism of PAFR is beneficial is selected from ocular indications such as diabetic retinopathy, proliferative and non-proliferative retinopathy, diabetic macular edema (DME), dry and exudative age-related macular degeneration (AMD), geographic atrophy, polypoidal choroidal vasculopathy (PCV) and choroidal neovascularization (CNV), from allergy and inflammation related conditions and diseases such as urticaria or NASH, and from diabetic complications associated with diabetic retinopathy such as diabetic macular edema, diabetic macular ischemia and proliferative diabetic retinopathy.

[0163] According to one embodiment, the patient is a human patient. Other features and advantages of the present invention will become apparent from the following more detailed examples which illustrate, by way of example, the principles of the invention.

[0164] Examples and Experimental Data The following examples are for illustrative purposes only and are not intended to limit the scope of the present invention in any way.

[0165] Abbreviation Ac Acetyl ACN Acetonitrile BPR Back Pressure Regulator BSA Bovine Serum Albumin Cbz benzyloxycarbonyl d number of days DABCO 1,4-diazabicyclo[2.2.2]octane DAD Diode Array Detector DBU 1,8-Diazabicyclo[5.4.0]undec-7-ene DCE 1,2-dichloroethane DCM Dichloromethane DMEM Dulbecco's Modified Eagle's Medium DMF N,N-Dimethylformamide DMSO Dimethyl sulfoxide EDTA Ethylenediaminetetraacetate EtOAc Ethyl acetate EtOH Ethanol h time HATU O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate HPLC High Performance Liquid Chromatography HPLC-MS High performance liquid chromatography-mass spectrometry IPA Isopropanol LC Liquid Chromatography LC-MS Liquid Chromatography - Mass Spectrometry M Molar concentration (mol / L) MeTHF 2-Methyltetrahydrofuran MeOH Methanol min minutes MS mass spectrometry NADPH Nicotinamide adenine dinucleotide phosphate NMP N-Methyl-2-pyrrolidone NMR nuclear magnetic resonance PET Polyethylene terephthalate pet. petroleum PyBop (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate R f Retention Factor rt / RT room temperature t R Retention time (HPLC / LC) Sc supercritical SFC Supercritical Fluid Chromatography TBTU O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate TFA Trifluoroacetic acid THF Tetrahydrofuran UV ultraviolet light

[0166] The terms "ambient temperature" and "room temperature" are used interchangeably and refer to a temperature of about 20°C, e.g., 15 to 25°C. in general, 1 H-NMR and / or mass spectra are obtained for the compounds prepared. Unless otherwise specified, compounds containing chiral centers have the stereochemistry as shown. The assignment of stereochemistry is made either by the use of chiral starting materials of known stereochemistry, by stereoselective synthesis of known stereochemistry, or by biological activity.

[0167] Analysis method: [Table 15]

[0168] [Table 16]

[0169] [Table 17]

[0170] [Table 18]

[0171] [Table 19]

[0172] [Table 20]

[0173] [Table 21]

[0174] [Table 22]

[0175] [Table 23]

[0176] Synthesis of intermediates: Intermediate 1 Methyl 9-(2-chlorophenyl)-3-methyl-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]Hexadeca-1(10),3,5,8,11-(15)-pentaene-13-carboxylate

[0177] [ka] Step 1: Methyl 2-amino-3-(2-chlorobenzoyl)-4H,5H,6H-cyclopenta[b]thiophene-5-carboxylate A mixture of 3-(2-chlorophenyl)-3-oxopropanenitrile (126 g), methyl 3-oxocyclopentane-1-carboxylate (100 g), sulfur (22.5 g), morpholine (61.8 mL) and MeOH (800 mL) is stirred at reflux for 4 hours. After cooling to room temperature, the reaction mixture is concentrated. The crude product is purified by silica gel column chromatography (petroleum ether / DCM 50:50) and then recrystallized from MeOH to give the title compound.

[0178] Step 2: Methyl 3-(2-chlorobenzoyl)-2-(2-bromoacetamido)-4H,5H,6H-cyclopenta[b]thiophene-5-carboxylate To a stirred mixture of methyl 2-amino-3-(2-chlorobenzoyl)-4H,5H,6H-cyclopenta[b]thiophene-5-carboxylate (100 g), NaHCO3 (30.0 g), toluene (1200 mL) and water (100 mL) is added bromoacetyl bromide (41.9 g) at 0° C. The cooling bath is removed and the mixture is stirred at 60° C. for 4 h. After cooling to room temperature, water is added and the resulting mixture is extracted with EtOAc (2×). The combined extracts are dried (Na2SO4) and concentrated. The residue is chromatographed on silica gel (petroleum ether / EtOAc 70:30) to give the title compound.

[0179] Step 3: Methyl 2-(2-aminoacetamido)-3-(2-chlorobenzoyl)-4H,5H,6H-cyclopenta[b]thiophene-5-carboxylate Methyl 3-(2-chlorobenzoyl)-2-(2-bromoacetamido)-4H,5H,6H-cyclopenta[b]thiophene-5-carboxylate (10.0 g) and ammonia (0.5 mol / L in THF; 70.0 mL) are added to a flask equipped with a stir bar at room temperature. The flask is sealed and the mixture is stirred overnight. The mixture is concentrated to remove excess ammonia and most of the THF, and EtOAc is added. The resulting mixture is washed with water, dried (Na2SO4), and concentrated to give the crude title compound, which is used in the next reaction step without further purification.

[0180] Step 4: Methyl 13-(2-chlorophenyl)-10-oxo-7-thia-9,12-diazatricyclo[6.5.0.0 2,6 ]Trideca-1(8),2(6),12-triene-4-carboxylate To a solution of methyl 2-(2-aminoacetamido)-3-(2-chlorobenzoyl)-4H,5H,6H-cyclopenta[b]thiophene-5-carboxylate (8.00 g) in toluene (80.0 mL) is added silica gel (3.05 g). To the resulting mixture is added 4 Å molecular sieves (1.00 g). The reaction mixture is stirred at 110° C. for 24 h. After cooling to room temperature, the mixture is filtered and concentrated, and the residue is chromatographed on silica gel (petroleum ether / EtOAc 70:30) to give the title compound.

[0181] Step 5: Methyl 9-(2-chlorophenyl)-3-methyl-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]-Hexadeca-1(10),3,5,8,11(15)-pentaene-13-carboxylate Methyl 13-(2-chlorophenyl)-10-oxo-7-thia-9,12-diazatricyclo[6.5.0.0 2,6 ]trideca-1(8),2(6),12-triene-4-carboxylate (5.05 g) in THF (50.0 mL) is added at room temperature with ClPO(OEt)2 (3.01 mL) and DBU (3.02 mL). The mixture is stirred for 10 min, then acetic acid hydrazide (1.56 g) is added. The mixture is stirred at room temperature for another 30 min, then at 60° C. for 4 h. After cooling to room temperature, EtOAc is added and the mixture is washed with water, aqueous NaHCO3 and brine. The organic phase is dried (MgSO4) and concentrated. The residue is chromatographed on silica gel (DCM / MeOH 99:1->95:5) to give the title compound.

[0182] Intermediate 2 9-(2-chlorophenyl)-3-methyl-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]Hexadeca-1(10),3,5,8,11(15)-pentaene-13-carboxylic acid

[0183] [ka] Methyl 9-(2-chlorophenyl)-3-methyl-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]Hexadeca-1(10),3,5,8,11(15)-pentaene-13-carboxylate (20.0 g) in THF (150 mL) is added at room temperature with NaOH (4 mol / L in water; 35.0 mL). The mixture is stirred at room temperature for 16 h. The mixture is diluted with water, HCl (4 mol / L in water) is added to adjust the pH value of the mixture to about 4.5, and then the mixture is extracted with DCM (5x). The combined organic extracts are washed with brine, dried (Na2SO4) and concentrated to give the crude title compound, which is used as such in the next reaction step.

[0184] Intermediate 3 and Reference Intermediate 4 (13S)-9-(2-chlorophenyl)-3-methyl-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]Hexadeca-1(10),3,5,8,11(15)-pentaene-13-carboxylic acid (intermediate 3) and (13R)-9-(2-chlorophenyl)-3-methyl-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]Hexadeca-1(10),3,5,8,11(15)-pentaene-13-carboxylic acid (Reference Intermediate 4)

[0185] [ka] 9-(2-chlorophenyl)-3-methyl-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15]Hexadeca-1(10),3,5,8,11(15)-pentaene-13-carboxylic acid (racemic mixture, 10.0 g) is dissolved (50 mg / mL in EtOH / DCM 2:1) and then resolved by SFC on a chiral phase [Column: Lux C4 (30 mm x 250 mm, 5 μm); Column temperature: 40 °C; Flow rate: 50 mL / min; BPR: 100 bar; Injection volume: 500 μL (25 mg); Isocratic conditions: 50:50 CO2:EtOH (0.2% v / v formic acid)] to give the isolated title compounds.

[0186] Intermediate 3:LC (Method 3):t R = 4.87 min; Mass Spectrum (ESI + ):m / z=399 / 401(Cl)[M+H] + ; Reference intermediate 4:LC (Method 3):t R = 4.26 min; Mass Spectrum (ESI + ):m / z=399 / 401(Cl)[M+H] + .

[0187] Intermediate 5 (13S)-9-(2-chlorophenyl)-3-methyl-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]-Hexadeca-1(10),3,5,8,11(15)-pentaene

[0188] [ka] (13S)-9-(2-chlorophenyl)-3-methyl-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15] To a mixture of hexadeca-1(10),3,5,8,11(15)-pentaene-13-carboxylic acid (10.0 mg), N,N-diisopropyl-ethylamine (0.010 mL) and DMF (1.00 mL) is added HATU (10.0 mg) at room temperature. After stirring for 5 min, morpholine (5.00 mg) is added and the resulting mixture is stirred for 1 h. The reaction mixture is diluted with DMF and purified by reverse phase chromatography (HPLC; ACN / water / aqueous ammonia) to give the title compound.

[0189] Intermediate 6 9-(2-chlorophenyl)-3-methyl-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]Hexa-deca-1(10),3,5,8,11(15)-pentaene

[0190] [ka] The title compound was prepared by a procedure similar to that described for intermediate 5, from 9-(2-chlorophenyl)-3-methyl-16-thia-2,4,5,8-tetraazatetra-cyclo[8.6.0.0 2,6 .0 11,15 ] Prepared from hexadeca-1(10),3,5,8,11(15)-pentaene-13-carboxylic acid and morpholine.

[0191] Reference Intermediate 7 (13R)-9-(2-chlorophenyl)-3-methyl-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]-Hexadeca-1(10),3,5,8,11(15)-pentaene

[0192] [ka] The title compound was prepared by a procedure similar to that described for intermediate 5, from (13R)-9-(2-chlorophenyl)-3-methyl-16-thia-2,4,5,8-tetraazatetra-cyclo[8.6.0.0 2,6 .0 11,15 ] Prepared from hexadeca-1(10),3,5,8,11(15)-pentaene-13-carboxylic acid and morpholine.

[0193] Intermediate 8 (9R,13S)-9-(2-chlorophenyl)-3-methyl-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]Hexadeca-1(10),3,5,11(15)-tetraene-13-carboxylic acid

[0194] [ka] To a stirred solution of N-Cbz-L-proline (48.1 g) in DCM (80 ml) is added tetrabutylammonium borohydride (16.6 g) in small portions at 0° C. After hydrogen evolution has ceased, the mixture is stirred for an additional hour at room temperature. The resulting solution is cooled to −10° C. and diluted with (13S)-9-(2-chlorophenyl)-3-methyl-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0]H2O. 2,6 .0 11,15 ]Hexadeca-1(10),3,5,8,11(15)-pentaene-13-carboxylic acid (8.6 g) in DCM (120 mL) is added dropwise and the reaction mixture is stirred at -10°C for 1 h and at room temperature for another 1 h. Aqueous HCl (1 M) is added to adjust the pH value of the mixture to 1 and the mixture is extracted with aqueous HCl (1 M, 3x). The pH of the combined aqueous layers is carefully adjusted with aqueous NaOH (4 M) until a pH of 4.5 is reached and a white precipitate appears. The mixture is extracted with DCM (3x). The combined organic extracts are dried (MgSO4) and concentrated. The crude product is purified by reverse phase chromatography (HPLC; ACN / water / TFA) to give the title compound. LC (Method 2):tR = 0.67 min; Mass spectrum (ESI+): m / z = 401 [M+H] + .

[0195] Reference Intermediate 9 (9R,13R)-9-(2-chlorophenyl)-3-methyl-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]Hexadeca-1(10),3,5,11(15)-tetraene-13-carboxylic acid

[0196] [ka] The title compound was prepared by a procedure similar to that described for intermediate 8, from (13R)-9-(2-chlorophenyl)-3-methyl-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]Hexadeca-1(10),3,5,8,11(15)-pentaene-13-carboxylic acid. LC (Method 2):t R = 0.70 min; Mass spectrum (ESI+): m / z = 401 [M+H] + .

[0197] Intermediate 10 (9S,13S)-9-(2-chlorophenyl)-3-methyl-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]Hexadeca-1(10),3,5,11(15)-tetraene-13-carboxylic acid

[0198] [ka] (13S)-9-(2-chlorophenyl)-3-methyl-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15]Hexadeca-1(10),3,5,8,11(15)-pentaene-13-carboxylic acid (1.00 g) is dissolved in DCM (35 mL) followed by addition of aqueous HCl (4 M, 1.25 mL) and sodium borohydride (379 mg). The reaction mixture is stirred at room temperature for 1.25 h. Aqueous HCl (4 M) is added and the mixture is stirred until gas evolution ceases, then MeOH and THF are added. The resulting precipitate is filtered and the filtrate is concentrated. The residue is dissolved in MeTHF and stirred at room temperature for 1 h. The resulting precipitate is filtered and washed with additional MeTHF. The crude product consisting of a diastereomeric mixture of intermediate 8 and the title compound is purified by reverse phase chromatography (HPLC; ACN / water / TFA) to give the isolated title compound. LC (Method 2):t R = 0.71 min; Mass spectrum (ESI+): m / z = 401 [M+H] + .

[0199] Intermediate 11 9-(4-chlorophenyl)-3-methyl-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2 , 6 .0 11 , 15 ]Hexadeca-1(10),3,5,8,11(15)-pentaene

[0200] [ka]

[0201] Step 1: Methyl 2-amino-3-(4-chlorobenzoyl)-4H,5H,6H-cyclopenta[b]thiophene-5-carboxylate The title compound is prepared from 3-(4-chlorophenyl)-3-oxopropanenitrile and methyl 3-oxocyclopentane-1-carboxylate following a procedure similar to that described in Step 1 of Intermediate 1. LC (Method 2):t R = 1.04 min; Mass Spectrum (ESI+ ):m / z=336[M+H] + . Step 2: Methyl 3-(4-chlorobenzoyl)-2-(2-bromoacetamido)-4H,5H,6H-cyclopenta[b]thiophene-5-carboxylate The title compound is prepared from methyl 2-amino-3-(4-chlorobenzoyl)-4H,5H,6H-cyclopenta[b]thiophene-5-carboxylate and bromo-acetyl bromide following a procedure similar to that described in step 2 of intermediate 1. LC (Method 2):t R = 1.14 min; Mass Spectrum (ESI + ):m / z=456 / 458(Br)[M+H] + . Step 3: Methyl 2-(2-aminoacetamido)-3-(4-chlorobenzoyl)-4H,5H,6H-cyclopenta[b]thiophene-5-carboxylate The title compound is prepared from methyl 3-(4-chlorobenzoyl)-2-(2-bromoacetamido)-4H,5H,6H-cyclopenta[b]thiophene-5-carboxylate following a procedure similar to that described in step 3 of intermediate 1. LC (Method 2):t R = 0.82 min; Mass Spectrum (ESI + ):m / z=393[M+H] + . Step 4: Methyl 13-(4-chlorophenyl)-10-oxo-7-thia-9,12-diazatricyclo[6.5.0.0 2,6 ]Trideca-1(8),2(6),12-triene-4-carboxylate The title compound is prepared from methyl 2-(2-aminoacetamido)-3-(4-chlorobenzoyl)-4H,5H,6H-cyclopenta[b]thiophene-5-carboxylate following a procedure similar to that described in step 4 of intermediate 1. LC (Method 2):t R = 0.75 min; Mass Spectrum (ESI + ):m / z=375[M+H] + . Step 5: Methyl 9-(4-chlorophenyl)-3-methyl-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]Hexadeca-1(10),3,5,8,11(15)-pentaene-13-carboxylate The title compound was prepared by synthesis of methyl 13-(4-chlorophenyl)-10-oxo-7-thia-9,12-diazatricyclo[6.5.0.0] following a procedure similar to that described in step 5 of intermediate 1. 2,6 ]-Trideca-1(8),2(6),12-triene-4-carboxylate. LC (Method 2):t R = 0.88 min; Mass Spectrum (ESI + ):m / z=413[M+H] + . Step 6: 9-(4-chlorophenyl)-3-methyl-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]Hexadeca-1(10),3,5,8,11(15)-pentaene-13-carboxylic acid The title compound was prepared by synthesis of methyl 9-(4-chlorophenyl)-3-methyl-16-thia-2,4,5,8-tetraazatetracyclo-[8.6.0.0] following a procedure similar to that described for intermediate 2. 2,6 .0 11,15 ]Hexadeca-1(10),3,5,8,11(15)-pentaene-13-carboxylate. LC (Method 2):t R = 0.75 min; Mass Spectrum (ESI + ):m / z=399[M+H] + . Step 7: 9-(4-chlorophenyl)-3-methyl-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]-Hexadeca-1(10),3,5,8,11(15)-pentaene The title compound was prepared by a procedure similar to that described for Intermediate 5, from 9-(4-chlorophenyl)-3-methyl-16-thia-2,4,5,8-tetraazatetracyclo-[8.6.0.0 2,6 .0 11,15 ] Prepared from hexadeca-1(10),3,5,8,11(15)-pentaene-13-carboxylic acid and morpholine. LC (Method 2):t R = 0.78 min (diastereomer); mass spectrum (ESI + ):m / z=468[M+H] + .

[0202] Intermediate 12 9-(2-Ethylphenyl)-3-methyl-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2 , 6 .0 11 , 15 ]Hexadeca-1(10),3,5,8,11(15)-pentaene

[0203] [ka]

[0204] Step 1: Methyl 2-amino-3-(2-ethylbenzoyl)-4H,5H,6H-cyclopenta[b]thiophene-5-carboxylate The title compound is prepared from 3-(2-ethylphenyl)-3-oxopropanenitrile and methyl 3-oxocyclopentane-1-carboxylate following a procedure similar to that described in Step 1 of Intermediate 1. LC (Method 2):t R = 1.05 min; Mass Spectrum (ESI + ):m / z=330[M+H] + . Step 2: Methyl 3-(2-ethylbenzoyl)-2-(2-bromoacetamido)-4H,5H,6H-cyclopenta[b]thiophene-5-carboxylate The title compound is prepared from methyl 2-amino-3-(2-ethylbenzoyl)-4H,5H,6H-cyclopenta[b]thiophene-5-carboxylate and bromo-acetyl bromide following a procedure similar to that described in step 2 of intermediate 1. LC (Method 2):t R = 1.17 min; Mass Spectrum (ESI + ):m / z=450 / 452(Br)[M+H] + . Step 3: Methyl 2-(2-aminoacetamido)-3-(2-ethylbenzoyl)-4H,5H,6H-cyclopenta[b]thiophene-5-carboxylate The title compound is prepared from methyl 3-(2-ethylbenzoyl)-2-(2-bromoacetamido)-4H,5H,6H-cyclopenta[b]thiophene-5-carboxylate following a procedure similar to that described in step 3 of intermediate 1. LC (Method 2):t R = 0.82 min; Mass Spectrum (ESI + ):m / z=387[M+H] + . Step 4: Methyl 13-(2-ethylphenyl)-10-oxo-7-thia-9,12-diazatricyclo[6.5.0.0 2,6 ]Trideca-1(8),2(6),12-triene-4-carboxylate The title compound is prepared from methyl 2-(2-aminoacetamido)-3-(2-ethylbenzoyl)-4H,5H,6H-cyclopenta[b]thiophene-5-carboxylate following a procedure similar to that described in step 4 of intermediate 1. LC (Method 2):t R = 0.75 min; Mass Spectrum (ESI + ):m / z=369[M+H] + . Step 5: Methyl 9-(2-ethylphenyl)-3-methyl-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]Hexadeca-1(10),3,5,8,11(15)-pentaene-13-carboxylate The title compound was prepared by synthesis of methyl 13-(2-ethylphenyl)-10-oxo-7-thia-9,12-diazatricyclo[6.5.0.0] following a procedure similar to that described in step 5 of intermediate 1. 2,6 ]-Trideca-1(8),2(6),12-triene-4-carboxylate. LC (Method 2):t R = 0.84 min; Mass Spectrum (ESI + ):m / z=407[M+H] + . Step 6: 9-(2-ethylphenyl)-3-methyl-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]Hexadeca-1(10),3,5,8,11(15)-pentaene-13-carboxylic acid The title compound was prepared by synthesis of methyl 9-(2-ethylphenyl)-3-methyl-16-thia-2,4,5,8-tetraazatetracyclo-[8.6.0.0] following a procedure similar to that described for intermediate 2. 2,6 .0 11,15 ]Hexadeca-1(10),3,5,8,11(15)-pentaene-13-carboxylate. LC (Method 2):t R = 0.74 min; Mass Spectrum (ESI + ):m / z=393[M+H] + . Step 7: 9-(2-ethylphenyl)-3-methyl-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]-Hexadeca-1(10),3,5,8,11(15)-pentaene The title compound was prepared by a procedure similar to that described for intermediate 5, from 9-(2-ethylphenyl)-3-methyl-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]-Hexadeca-1(10),3,5,8,11(15)-pentaene-13-carboxylic acid and morpholine. LC (Method 2): R= 0.75 min; Mass Spectrum (ESI + ):m / z=462[M+H] + .

[0205] Intermediate 13 9-(2-Methoxyphenyl)-3-methyl-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2 , 6 .0 11 , 15 ]-Hexadeca-1(10),3,5,8,11(15)-pentaene

[0206] [ka]

[0207] Step 1: Methyl 2-amino-3-(2-methoxybenzoyl)-4H,5H,6H-cyclopenta[b]thiophene-5-carboxylate The title compound is prepared from 3-(2-methoxyphenyl)-3-oxopropanenitrile and methyl 3-oxocyclopentane-1-carboxylate following a procedure similar to that described in Step 1 of Intermediate 1. LC (Method 2):t R = 0.95 min; Mass Spectrum (ESI + ):m / z=332[M+H] + . Step 2: Methyl 3-(2-methoxybenzoyl)-2-(2-bromoacetamido)-4H,5H,6H-cyclopenta[b]thiophene-5-carboxylate The title compound is prepared from methyl 2-amino-3-(2-methoxybenzoyl)-4H,5H,6H-cyclopenta[b]thiophene-5-carboxylate and bromo-acetyl bromide following a procedure similar to that described in step 2 of intermediate 1. LC (Method 2):t R = 1.08 min; Mass Spectrum (ESI + ):m / z=452 / 454(Br)[M+H] + . Step 3: Methyl 2-(2-aminoacetamido)-3-(2-methoxybenzoyl)-4H,5H,6H-cyclopenta[b]thiophene-5-carboxylate The title compound is prepared from methyl 3-(2-methoxybenzoyl)-2-(2-bromoacetamido)-4H,5H,6H-cyclopenta[b]thiophene-5-carboxylate following a procedure similar to that described in step 3 of intermediate 1. LC (Method 2):t R = 0.92 min; Mass Spectrum (ESI + ):m / z=389[M+H] + . Step 4: Methyl 13-(2-methoxyphenyl)-10-oxo-7-thia-9,12-diazatricyclo[6.5.0.0 2,6 ]Trideca-1(8),2(6),12-triene-4-carboxylate The title compound is prepared from methyl 2-(2-aminoacetamido)-3-(2-methoxybenzoyl)-4H,5H,6H-cyclopenta[b]thiophene-5-carboxylate following a procedure similar to that described in step 4 of intermediate 1. LC (Method 2):t R = 0.70 min; Mass Spectrum (ESI + ):m / z=371[M+H] + . Step 5: Methyl 9-(2-methoxyphenyl)-3-methyl-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]Hexadeca-1(10),3,5,8,11(15)-pentaene-13-carboxylate The title compound was prepared by synthesis of methyl 13-(2-methoxyphenyl)-10-oxo-7-thia-9,12-diazatricyclo[6.5.0.0] following a procedure similar to that described in step 5 of intermediate 1. 2,6 ]-Trideca-1(8),2(6),12-triene-4-carboxylate. LC (Method 2):t R = 0.73 min; Mass Spectrum (ESI +):m / z=409[M+H] + . Step 6: 9-(2-Methoxyphenyl)-3-methyl-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]Hexadeca-1(10),3,5,8,11(15)-pentaene-13-carboxylic acid The title compound was prepared by synthesis of methyl 9-(2-methoxyphenyl)-3-methyl-16-thia-2,4,5,8-tetraazatetracyclo-[8.6.0.0] following a procedure similar to that described for intermediate 2. 2,6 .0 11,15 ]Hexadeca-1(10),3,5,8,11(15)-pentaene-13-carboxylate. LC (Method 2):t R = 0.64 min; Mass Spectrum (ESI + ):m / z=395[M+H] + . Step 7: 9-(2-Methoxyphenyl)-3-methyl-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo-[8.6.0.0 2,6 .0 11,15 ]-Hexadeca-1(10),3,5,8,11(15)-pentaene The title compound was prepared by a procedure similar to that described for Intermediate 5, from 9-(2-methoxyphenyl)-3-methyl-16-thia-2,4,5,8-tetraazatetracyclo-[8.6.0.0 2,6 .0 11,15 ] Prepared from hexadeca-1(10),3,5,8,11(15)-pentaene-13-carboxylic acid and morpholine. LC (Method 2):t R = 0.66 min (diastereomer); mass spectrum (ESI + ):m / z=464[M+H] + .

[0208] Intermediate 14 9-(2-Fluorophenyl)-3-methyl-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.02 , 6 .0 11 , 15 ]-Hexadeca-1(10),3,5,8,11(15)-pentaene

[0209] [ka]

[0210] Step 1: Methyl 2-amino-3-(2-fluorobenzoyl)-4H,5H,6H-cyclopenta[b]thiophene-5-carboxylate The title compound is prepared from 3-(2-fluorophenyl)-3-oxopropanenitrile and methyl 3-oxocyclopentane-1-carboxylate following a procedure similar to that described in Step 1 of Intermediate 1. LC (Method 2):t R = 0.98 min; Mass Spectrum (ESI + ):m / z=320[M+H] + . Step 2: Methyl 3-(2-fluorobenzoyl)-2-(2-bromoacetamido)-4H,5H,6H-cyclopenta[b]thiophene-5-carboxylate The title compound is prepared from methyl 2-amino-3-(2-fluorobenzoyl)-4H,5H,6H-cyclopenta[b]thiophene-5-carboxylate and bromo-acetyl bromide following a procedure similar to that described in step 2 of intermediate 1. LC (Method 2):t R = 1.11 min; Mass Spectrum (ESI + ):m / z=440 / 442(Br)[M+H] + . Step 3: Methyl 2-(2-aminoacetamido)-3-(2-fluorobenzoyl)-4H,5H,6H-cyclopenta[b]thiophene-5-carboxylate The title compound is prepared from methyl 3-(2-fluorobenzoyl)-2-(2-bromoacetamido)-4H,5H,6H-cyclopenta[b]thiophene-5-carboxylate following a procedure similar to that described in step 3 of intermediate 1. LC (Method 2):t R = 0.76 min; Mass Spectrum (ESI + ):m / z=377[M+H] + . Step 4: Methyl 13-(2-fluorophenyl)-10-oxo-7-thia-9,12-diazatricyclo[6.5.0.0 2,6 ]Trideca-1(8),2(6),12-triene-4-carboxylate The title compound is prepared from methyl 2-(2-aminoacetamido)-3-(2-fluorobenzoyl)-4H,5H,6H-cyclopenta[b]thiophene-5-carboxylate following a procedure similar to that described in step 4 of intermediate 1. LC (Method 2):t R = 0.70 min; Mass Spectrum (ESI + ):m / z=359[M+H] + . Step 5: Methyl 9-(2-fluorophenyl)-3-methyl-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]Hexadeca-1(10),3,5,8,11(15)-pentaene-13-carboxylate The title compound was prepared by synthesis of methyl 13-(2-fluorophenyl)-10-oxo-7-thia-9,12-diazatricyclo[6.5.0.0] following a procedure similar to that described in step 5 of intermediate 1. 2,6 ]-Trideca-1(8),2(6),12-triene-4-carboxylate. LC (Method 2):t R = 0.82 min; Mass Spectrum (ESI + ):m / z=397[M+H] + . Step 6: 9-(2-fluorophenyl)-3-methyl-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]Hexadeca-1(10),3,5,8,11(15)-pentaene-13-carboxylic acid The title compound was prepared by synthesis of methyl 9-(2-fluorophenyl)-3-methyl-16-thia-2,4,5,8-tetraazatetracyclo-[8.6.0.0] following a procedure similar to that described for intermediate 2. 2,6 .0 11,15 ]Hexadeca-1(10),3,5,8,11(15)-pentaene-13-carboxylate. LC (Method 2):t R = 0.71 min; Mass Spectrum (ESI + ):m / z=383[M+H] + . Step 7: 9-(2-fluorophenyl)-3-methyl-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]-Hexadeca-1(10),3,5,8,11(15)-pentaene The title compound was prepared by a procedure similar to that described for intermediate 5, from 9-(2-fluorophenyl)-3-methyl-16-thia-2,4,5,8-tetraazatetracyclo-[8.6.0.0 2,6 .0 11,15 ] Prepared from hexadeca-1(10),3,5,8,11(15)-pentaene-13-carboxylic acid and morpholine. LC (Method 2): R = 0.73 min; Mass Spectrum (ESI + ):m / z=452[M+H] + .

[0211] Intermediate 15 3-Methyl-13-(morpholine-4-carbonyl)-9-[2-(trifluoromethyl)phenyl]-16-thia-2,4,5,8-tetraazatetracyclo-[8.6.0.0 2 , 6 .0 11 , 15]Hexadeca-1(10),3,5,8,11(15)-pentaene

[0212] [ka]

[0213] Step 1: Methyl 2-amino-3-[2-(trifluoromethyl)benzoyl]-4H,5H,6H-cyclopenta[b]thiophene-5-carboxylate The title compound is prepared from 2-(trifluoromethyl)benzoyl cyanide and methyl 3-oxocyclopentane-1-carboxylate following a procedure similar to that described in step 1 of intermediate 1. Mass spectrum (ESI + ):m / z=370[M+H] + . Step 2: Methyl 2-(2-bromoacetamido)-3-[2-(trifluoromethyl)benzoyl]-4H,5H,6H-cyclopenta[b]thiophene-5-carboxylate The title compound is prepared from methyl 2-amino-3-[2-(trifluoromethyl)benzoyl]-4H,5H,6H-cyclopenta[b]thiophene-5-carboxylate and bromo-acetyl bromide following a procedure similar to that described in step 2 of intermediate 1. LC (Method 2):t R = 1.14 min; Mass Spectrum (ESI + ):m / z=490 / 492(Br)[M+H] + . Step 3: Methyl 2-(2-aminoacetamido)-3-[2-(trifluoromethyl)benzoyl]-4H,5H,6H-cyclopenta[b]thiophene-5-carboxylate The title compound is prepared from methyl 2-(2-bromoacetamido)-3-[2-(trifluoromethyl)benzoyl]-4H,5H,6H-cyclopenta[b]thiophene-5-carboxylate following a procedure similar to that described in step 3 of intermediate 1. LC (Method 2):t R = 0.80 min; Mass Spectrum (ESI +):m / z=427[M+H] + . Step 4: Methyl 10-oxo-13-[2-(trifluoromethyl)phenyl]-7-thia-9,12-diazatricyclo[6.5.0.0 2,6 ]Trideca-1(8),2(6),12-triene-4-carboxylate The title compound is prepared from methyl 2-(2-aminoacetamido)-3-[2-(trifluoromethyl)benzoyl]-4H,5H,6H-cyclopenta[b]thiophene-5-carboxylate following a procedure similar to that described in step 4 of intermediate 1. LC (Method 2):t R = 0.78 min; Mass Spectrum (ESI + ):m / z=409[M+H] + . Step 5: Methyl 3-methyl-9-[2-(trifluoromethyl)phenyl]-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]Hexadeca-1(10),3,5,8,11(15)-pentaene-13-carboxylate The title compound was prepared by the procedure similar to that described in step 5 of intermediate 1 from methyl 10-oxo-13-[2-(trifluoromethyl)phenyl]-7-thia-9,12-diazatricyclo-[6.5.0.0 2,6 ]Trideca-1(8),2(6),12-triene-4-carboxylate. LC (Method 2): R = 0.91 min; Mass Spectrum (ESI + ):m / z=447[M+H] + . Step 6: 3-Methyl-9-[2-(trifluoromethyl)phenyl]-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]Hexadeca-1(10),3,5,8,11(15)-pentaene-13-carboxylic acid The title compound was prepared by synthesis of methyl 3-methyl-9-[2-(trifluoromethyl)phenyl]-16-thia-2,4,5,8-tetraazatetracyclo-[8.6.0.0] following a procedure similar to that described for intermediate 2. 2,6 .0 11,15 ]Hexadeca-1(10),3,5,8,11(15)-pentaene-13-carboxylate. LC (Method 2):t R = 0.80 min; Mass Spectrum (ESI + ):m / z=433[M+H] + . Step 7: 3-Methyl-13-(morpholine-4-carbonyl)-9-[2-(trifluoromethyl)phenyl]-16-thia-2,4,5,8-tetraazatetracyclo-[8.6.0.0 2,6 .0 11,15 ]Hexadeca-1(10),3,5,8,11(15)-pentaene The title compound was prepared by the procedure similar to that described for Intermediate 5, from 3-methyl-9-[2-(trifluoromethyl)phenyl]-16-thia-2,4,5,8-tetraazatetracyclo-[8.6.0.0 2,6 .0 11,15 ] Prepared from hexadeca-1(10),3,5,8,11(15)-pentaene-13-carboxylic acid and morpholine. LC (Method 2): R = 0.82 min; Mass Spectrum (ESI + ):m / z=502[M+H] + .

[0214] Intermediate 16 9-(2-Bromophenyl)-3-methyl-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2 , 6 .0 11, , 15 ]-Hexadeca-1(10),3,5,8,11(15)-pentaene

[0215] [ka]

[0216] Step 1: Methyl 2-amino-3-(2-bromobenzoyl)-4H,5H,6H-cyclopenta[b]thiophene-5-carboxylate The title compound is prepared from 3-(2-bromophenyl)-3-oxopropanenitrile and methyl 3-oxocyclopentane-1-carboxylate following a procedure similar to that described in Step 1 of Intermediate 1. LC (Method 2):t R = 0.99 min; Mass Spectrum (ESI + ):m / z=380 / 382(Br)[M+H] + . Step 2: Methyl 3-(2-bromobenzoyl)-2-(2-bromoacetamido)-4H,5H,6H-cyclopenta[b]thiophene-5-carboxylate The title compound is prepared from methyl 2-amino-3-(2-bromobenzoyl)-4H,5H,6H-cyclopenta[b]thiophene-5-carboxylate and bromo-acetyl bromide following a procedure similar to that described in step 2 of intermediate 1. LC (Method 2):t R = 1.14 min; Mass Spectrum (ESI + ):m / z=500 / 502 / 504(2Br)[M+H] + . Step 3: Methyl 2-(2-aminoacetamido)-3-(2-bromobenzoyl)-4H,5H,6H-cyclopenta[b]thiophene-5-carboxylate The title compound is prepared from methyl 3-(2-bromobenzoyl)-2-(2-bromoacetamido)-4H,5H,6H-cyclopenta[b]thiophene-5-carboxylate following a procedure similar to that described in step 3 of intermediate 1. LC (Method 2):t R = 0.79 min; Mass Spectrum (ESI + ):m / z=437 / 439(Br)[M+H] + . Step 4: Methyl 13-(2-bromophenyl)-10-oxo-7-thia-9,12-diazatricyclo[6.5.0.0 2,6 ]Trideca-1(8),2(6),12-triene-4-carboxylate The title compound is prepared from methyl 2-(2-aminoacetamido)-3-(2-bromobenzoyl)-4H,5H,6H-cyclopenta[b]thiophene-5-carboxylate following a procedure similar to that described in step 4 of intermediate 1. LC (Method 2):t R = 0.74 min; Mass Spectrum (ESI + ):m / z=419 / 421(Br)[M+H] + . Step 5: Methyl 9-(2-bromophenyl)-3-methyl-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]Hexadeca-1(10),3,5,8,11(15)-pentaene-13-carboxylate The title compound was prepared by synthesis of methyl 13-(2-bromophenyl)-10-oxo-7-thia-9,12-diazatricyclo[6.5.0.0] following a procedure similar to that described in step 5 of intermediate 1. 2,6 ]-Trideca-1(8),2(6),12-triene-4-carboxylate. LC (Method 2):t R = 0.88 min; Mass Spectrum (ESI + ):m / z=457 / 459(Br)[M+H] + . Step 6: 9-(2-bromophenyl)-3-methyl-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]Hexadeca-1(10),3,5,8,11(15)-pentaene-13-carboxylic acid The title compound was prepared by synthesis of methyl 9-(2-bromophenyl)-3-methyl-16-thia-2,4,5,8-tetraazatetracyclo-[8.6.0.0] following a procedure similar to that described for intermediate 2. 2,6 .0 11,15]Hexadeca-1(10),3,5,8,11(15)-pentaene-13-carboxylate. LC (Method 2):t R = 0.78 min; Mass Spectrum (ESI + ):m / z=443 / 445(Br)[M+H] + . Step 7: 9-(2-bromophenyl)-3-methyl-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]-Hexadeca-1(10),3,5,8,11(15)-pentaene The title compound was prepared by a procedure similar to that described for intermediate 5, from 9-(2-bromophenyl)-3-methyl-16-thia-2,4,5,8-tetraazatetracyclo-[8.6.0.0 2,6 .0 11,15 ] Prepared from hexadeca-1(10),3,5,8,11(15)-pentaene-13-carboxylic acid and morpholine. LC (Method 2):t R = 0.79 min; Mass Spectrum (ESI + ):m / z=512 / 514(Br)[M+H] + .

[0217] Intermediate 17 9-(3,5-difluorophenyl)-3-methyl-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2 , 6 .0 11 , 15 ]Hexadeca-1(10),3,5,8,11(15)-pentaene

[0218] [ka]

[0219] Step 1: Methyl 2-amino-3-(3,5-difluorobenzoyl)-4H,5H,6H-cyclopenta[b]thiophene-5-carboxylate The title compound can be prepared by the procedure similar to that described in Step 1 of Intermediate 1, by the addition of 3-(3,5-difluorophenyl)-3-oxopropanenitrile and methyl 3-oxocyclopentane-1-carboxylate. Prepare from: LC (Method 2):t R = 1.04 min; Mass Spectrum (ESI + ):m / z=338[M+H] + . Step 2: Methyl 2-(2-bromoacetamido)-3-(3,5-difluorobenzoyl)-4H,5H,6H-cyclopenta[b]thiophene-5-carboxylate The title compound is prepared from methyl 2-amino-3-(3,5-difluorobenzoyl)-4H,5H,6H-cyclopenta[b]thiophene-5-carboxylate and bromo-acetyl bromide following a procedure similar to that described in step 2 of intermediate 1. LC (Method 2):t R = 1.14 min; Mass Spectrum (ESI + ):m / z=460[M+H] + . Step 3: Methyl 13-(3,5-difluorophenyl)-10-oxo-7-thia-9,12-diazatricyclo[6.5.0.0 2,6 ]Trideca-1(8),2(6),12-triene-4-carboxylate The title compound is prepared directly from methyl 2-(2-bromoacetamido)-3-(3,5-difluorobenzoyl)-4H,5H,6H-cyclopenta[b]thiophene-5-carboxylate following a procedure similar to that described in step 3 of intermediate 1. LC (Method 2):t R = 0.77 min; Mass Spectrum (ESI + ):m / z=377[M+H] + . Step 4: Methyl 9-(3,5-difluorophenyl)-3-methyl-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15]Hexadeca-1(10),3,5,8,11(15)-pentaene-13-carboxylate The title compound was prepared by reacting methyl 13-(3,5-difluorophenyl)-10-oxo-7-thia-9,12-diazatricyclo-[6.5.0.0] following a procedure similar to that described in step 5 of intermediate 1. 2,6 ]Trideca-1(8),2(6),12-triene-4-carboxylate. LC (Method 2): R = 0.91 min; Mass Spectrum (ESI + ):m / z=415[M+H] + . Step 5: 9-(3,5-difluorophenyl)-3-methyl-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]Hexadeca-1(10),3,5,8,11(15)-pentaene-13-carboxylic acid The title compound was prepared by synthesis of methyl 9-(3,5-difluorophenyl)-3-methyl-16-thia-2,4,5,8-tetraazatetracyclo-[8.6.0.0] following a procedure similar to that described for intermediate 2. 2,6 .0 11,15 ]Hexadeca-1(10),3,5,8,11(15)-pentaene-13-carboxylate. LC (Method 2):t R = 0.79 min; Mass Spectrum (ESI + ):m / z=401[M+H] + . Step 6: 9-(3,5-difluorophenyl)-3-methyl-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo-[8.6.0.0 2,6 .0 11,15 ]Hexadeca-1(10),3,5,8,11(15)-pentaene The title compound was prepared by a procedure similar to that described for intermediate 5, from 9-(3,5-difluorophenyl)-3-methyl-16-thia-2,4,5,8-tetraazatetracyclo-[8.6.0.0 2,6 .0 11,15] Prepared from hexadeca-1(10),3,5,8,11(15)-pentaene-13-carboxylic acid and morpholine. LC (Method 2): R = 0.81 min; Mass Spectrum (ESI + ):m / z=470[M+H] + .

[0220] Intermediate 18 3-Methyl-9-(methylsulfanyl)-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]Hexadeca-1(10),3,5,8,11(15)-pentaene

[0221] [ka]

[0222] Step 1: 3,5-Dimethyl-2-amino-4H,5H,6H-cyclopenta[b]thiophene-3,5-dicarboxylate The title compound is prepared from methyl cyanoacetate and methyl 3-oxocyclopentane-1-carboxylate following a procedure similar to that described in Step 1 of Intermediate 1. LC (Method 2):t R = 1.93 min; Mass Spectrum (ESI + ):m / z=256[M+H] + . Step 2: 3,5-Dimethyl 2-(2-methoxyacetamido)-4H,5H,6H-cyclopenta[b]thiophene-3,5-dicarboxylate 3,5-Dimethyl 2-amino-4H,5H,6H-cyclopenta[b]thiophene-3,5-dicarboxylate (26.8 g) and pyridine (12.7 mL) are dissolved in DCM (200 mL). Methoxyacetyl chloride (9.56 mL) is added and the reaction mixture is stirred at room temperature for 1 h. The reaction is quenched by the addition of water, then the organic phase is separated, dried (Na2SO4) and concentrated to dryness to give the title compound. LC (Method 2):t R = 1.01 min; Mass spectrum (ESI+): m / z = 328 [M+H] + . Step 3: 3,5-Dimethyl 2-(2-methoxyethanethioamido)-4H,5H,6H-cyclopenta[b]thiophene-3,5-dicarboxylate 3,5-Dimethyl 2-(2-methoxyacetamido)-4H,5H,6H-cyclopenta[b]thiophene-3,5-dicarboxylate (36.0 g) is dissolved in 1,4-dioxane (150 mL) and Lawesson's reagent (48.9 g) is added. The reaction is stirred at 80° C. for 6 h. The reaction mixture is filtered and the filtrate is concentrated to dryness. The residue is triturated with methanol to give the title compound. LC (Method 2):t R = 1.16 min; Mass spectrum (ESI+): m / z = 344 [M+H] + . Step 4: 3,5-Dimethyl 2-[3-(methoxymethyl)-5-methyl-4H-1,2,4-triazol-4-yl]-4H,5H,6H-cyclopenta[b]thiophene-3,5-dicarboxylate 3,5-Dimethyl 2-(2-methoxyethanethioamido)-4H,5H,6H-cyclopenta[b]thiophene-3,5-dicarboxylate (3.00 g) is dissolved in THF (45 mL) and hydrazine hydrate (0.849 mL) is added. The reaction mixture is stirred at room temperature for 0.75 h. N,N-Dimethylacetamide dimethyl acetal (5.1 mL) is added and the reaction is stirred at room temperature for an additional 1.5 h. Acetic acid (15.3 mL) is added and the reaction mixture is stirred at 100° C. for 3.5 days. The reaction mixture is diluted with water and EtOAc, basified with NaHCO3, and extracted with EtOAc (3×). The combined organic extracts are dried (MgSO4) and concentrated to dryness. The residue is chromatographed on silica gel (petroleum ether / EtOAc / methanol 80:16:4 to 20:64:16) to give the title compound. LC (Method 1):t R = 0.82 min; Mass spectrum (ESI+): m / z = 366 [M+H] + . Step 5: 3,5-Dimethyl 2-[3-(hydroxymethyl)-5-methyl-4H-1,2,4-triazol-4-yl]-4H,5H,6H-cyclopenta[b]thiophene-3,5-dicarboxylate 3,5-Dimethyl 2-[3-(methoxymethyl)-5-methyl-4H-1,2,4-triazol-4-yl]-4H,5H,6H-cyclopenta[b]thiophene-3,5-dicarboxylate (2.79 g) is dissolved in DCM (40 mL) and then boron tribromide (1M in DCM, 15.3 mL) is added. The reaction mixture is stirred at room temperature for 1.75 h. The reaction mixture is diluted in DCM and saturated aqueous NaHCO3, stirred for 15 min, and then extracted with DCM (2x). The combined organic extracts are dried (MgSO4) and concentrated to give the title compound. LC (Method 2):t R = 0.75 min; Mass spectrum (ESI+): m / z = 352 [M+H] + . Step 6: 3,5-Dimethyl 2-[3-(bromomethyl)-5-methyl-4H-1,2,4-triazol-4-yl]-4H,5H,6H-cyclopenta[b]thiophene-3,5-dicarboxylate 3,5-Dimethyl 2-[3-(hydroxymethyl)-5-methyl-4H-1,2,4-triazol-4-yl]-4H,5H,6H-cyclopenta[b]thiophene-3,5-dicarboxylate (2.47 g) is dissolved in DCM (30 mL) and then Et3N (2.2 mL) and methanesulfonyl bromide (1.3 mL) are added. The reaction mixture is stirred at room temperature for 3 h. The reaction mixture is diluted with saturated aqueous NaHCO3 and extracted with DCM (2x). The combined organic extracts are dried (MgSO4) and concentrated to give the title compound, which is used immediately in the next step. LC (Method 2):t R = 0.88 min; Mass spectrum (ESI+): m / z = 414 / 416 (Br) [M+H] + . Step 7: Methyl 3-methyl-9-oxo-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.02,6 .0 11,15 ]Hexadeca-1(10),3,5,11(15)-tetraene-13-carboxylate 3,5-Dimethyl 2-[3-(bromomethyl)-5-methyl-4H-1,2,4-triazol-4-yl]-4H,5H,6H-cyclopenta[b]thiophene-3,5-dicarboxylate (3.20 g) is dissolved in ammonia in methanol (7 M, 30 mL). The reaction mixture is stirred at room temperature for 3.75 h, after which the mixture is concentrated to dryness. The resulting crude intermediate is dissolved in methanol (40 mL) and Et3N (1.0 mL) is added. The reaction mixture is stirred at 80° C. for 7 h, after which the mixture is concentrated to dryness. The residue is chromatographed on silica gel (petroleum ether / EtOAc / methanol 95:4:1 to 0:80:20) to give the title compound. LC (Method 2):t R = 0.71 min; Mass spectrum (ESI+): m / z = 319 [M+H] + . Step 8: Methyl 3-methyl-9-sulfanylidene-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]Hexadeca-1(10),3,5,11(15)-tetraene-13-carboxylate Methyl 3-methyl-9-oxo-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]Hexadeca-1(10),3,5,11(15)-tetraene-13-carboxylate (1.00 g) and Lawesson's reagent (3.00 g) are dissolved in 1,4-dioxane (20 mL). The reaction mixture is stirred at 65° C. for 16 h. An additional portion of Lawesson's reagent (1.00 g) is added and stirring is continued at 65° C. for 10 h. The reaction mixture is diluted with aqueous NaHCO3 and extracted with DCM (2×). The combined organic extracts are washed with brine, dried (MgSO4), and concentrated to give the title compound, which is used immediately in the next reaction. LC (Method 2):t R = 0.79 min; Mass spectrum (ESI+): m / z = 335 [M+H] +. Step 9: 3-Methyl-9-sulfanylidene-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]Hexadeca-1(10),3,5,11(15)-tetraene-13-carboxylic acid Methyl 3-methyl-9-sulfanylidene-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]Hexadeca-1(10),3,5,11(15)-tetraene-13-carboxylate (1.70 g) is suspended in methanol (20 mL) and aqueous NaOH (4 M, 5.00 mL) is added. The reaction mixture is stirred at room temperature for 1 h, after which the mixture is concentrated to near dryness. The reaction mixture is acidified with TFA and the resulting precipitate is collected by filtration to give the title compound. LC (Method 2):t R = 0.68 min; Mass spectrum (ESI+): m / z = 321 [M+H] + . Step 10: 3-Methyl-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]Hexadeca-1(10),3,5,11(15)-tetraene-9-thione 3-Methyl-9-sulfanilidene-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]Hexadeca-1(10),3,5,11(15)-tetraene-13-carboxylic acid (1.65 g) and 1,1'-carbonyldiimidazole (0.92 g) are dissolved in DMF (30 mL). The solution is stirred at 50°C for 1 h. Morpholine (0.68 mL) is added and the solution is stirred at room temperature for 1 h. The reaction mixture is diluted with water / brine (1:1) and extracted with EtOAc (3x). The combined organic extracts are washed with brine, dried (MgSO4) and concentrated to dryness. The residue is purified by reverse phase chromatography (HPLC; ACN / water / TFA) to give the title compound. LC (Method 2):tR = 0.71 min; Mass spectrum (ESI+): m / z = 390 [M+H] + . Step 11: 3-Methyl-9-(methylsulfanyl)-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]Hexadeca-1(10),3,5,8,11(15)-pentaene 3-Methyl-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]Hexadeca-1(10),3,5,11(15)-tetraene-9-thione (0.60 g) and potassium tert-butoxide (0.175 g) are dissolved in acetone (10 mL) and then methyl iodide (0.77 mL) is added. The solution is stirred at room temperature for 1 h. The reaction mixture is diluted with water and extracted with DCM (2x). The combined organic extracts are washed with brine, dried (MgSO4) and concentrated to dryness to give the title compound. LC (Method 2):t R = 0.70 min; Mass spectrum (ESI+): m / z = 404 [M+H] + .

[0223] Intermediate 19 9-(2-cyclopropylphenyl)-3-methyl-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]-Hexadeca-1(10),3,5,8,11(15)-pentaene

[0224] [ka] 3-Methyl-9-(methylsulfanyl)-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15]Hexadeca-1(10),3,5,8,11(15)-pentaene (100 mg) and copper(I) 3-methylsalicylate (160 mg) are suspended in NMP (2.00 mL) under argon atmosphere. (2-Cyclopropylphenyl)boronic acid (100 mg) and tetrakis(triphenylphosphine)palladium(0) (30 mg) are added and the reaction mixture is stirred at 50° C. for 1 h. If the conversion is incomplete, additional amounts of (2-cyclopropylphenyl)boronic acid (50 mg) and tetrakis(triphenylphosphine)palladium(0) (30 mg) are added and stirring is continued at 50° C. for 2 h. Upon completion, the reaction mixture is diluted with aqueous NaHCO3 (1M) and extracted with EtOAc (3×). The combined organic extracts are dried (MgSO4) and concentrated. The crude product is purified by reverse phase chromatography (HPLC; ACN / water / NH3) to give the title compound. LC (Method 2): R = 0.75 min; Mass spectrum (ESI+): m / z = 474 [M+H] + .

[0225] Intermediate 20 {2-[3-methyl-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]Hexadeca-1(10),3,5,8,11(15)-pentaen-9-yl]phenyl}methanol

[0226] [ka] The title compound was prepared by a procedure similar to that described for intermediate 19 from 3-methyl-9-(methylsulfanyl)-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ] Prepared from hexadeca-1(10),3,5,8,11(15)-pentaene and 2-(hydroxymethyl)phenylboronic acid. LC (Method 2):t R= 0.66 min; Mass spectrum (ESI+): m / z = 464 [M+H] + .

[0227] Intermediate 21 2-[3-methyl-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]Hexadeca-1(10),3,5,8,11(15)-pentaen-9-yl]phenol

[0228] [ka] The title compound was prepared by a procedure similar to that described for intermediate 19 from 3-methyl-9-(methylsulfanyl)-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ] Prepared from hexadeca-1(10),3,5,8,11(15)-pentaene and (2-hydroxyphenyl)boronic acid. LC (Method 2):t R = 0.73 min; Mass spectrum (ESI+): m / z = 450 [M+H] + .

[0229] Intermediate 22 9-(2-chloro-5-methoxyphenyl)-3-methyl-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo-[8.6.0.0 2,6 .0 11,15 ]Hexadeca-1(10),3,5,8,11(15)-pentaene

[0230] [ka] The title compound was prepared by a procedure similar to that described for intermediate 19 from 3-methyl-9-(methylsulfanyl)-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.02,6 .0 11,15 ] Prepared from hexadeca-1(10),3,5,8,11(15)-pentaene and (2-chloro-5-methoxyphenyl)boronic acid. LC (Method 2):t R = 0.84 min; Mass spectrum (ESI+): m / z = 498 [M+H] + .

[0231] Intermediate 23 9-(2-Methylphenyl)-3-methyl-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]-Hexadeca-1(10),3,5,8,11(15)-pentaene

[0232] [ka] Stir bar, 9-(2-chlorophenyl)-3-methyl-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]Hexa-deca-1(10),3,5,8,11(15)-pentaene (50 mg), methylboronic acid (13 mg), K3PO4 (71 mg), Pd(OAc)2 (1.2 mg) and dicyclohexyl(2',6'-dimethoxybiphenyl-2-yl)phosphine (4.4 mg) are purged with Ar for 5 min in a vial. Water (25 μL) and toluene (0.25 mL) are added, the vial is sealed and the mixture is stirred in a microwave oven at 140 °C for 30 min. An additional portion of methylboronic acid (13 mg), Pd(OAc)2 (1.2 mg) and dicyclohexyl(2',6'-dimethoxybiphenyl-2-yl)phosphine (4.4 mg) is added at room temperature and the mixture is stirred in a microwave oven at 140 °C for 30 min. After cooling to room temperature, MeOH is added, the resulting mixture is filtered, and the filtrate is chromatographed on reverse phase (HPLC; ACN / water / TFA) to give the title compound. LC (Method 2):tR = 0.72 min; Mass spectrum (ESI+): m / z = 448 [M+H] + .

[0233] Intermediate 24 3-Methyl-13-(morpholine-4-carbonyl)-9-phenyl-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]Hexadeca-1(10),3,5,8,11(15)-pentaene

[0234] [ka] The title compound can be prepared by the application of a two-step procedure involving hydrolysis of the methyl ester (similar to that described for Intermediate 2) and amide coupling of the resulting carboxylic acid with morpholine (similar to that described for Intermediate 5), to afford the methyl 3-methyl-9-phenyl-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0]. 2,6 .0 11,15 ]Hexadeca-1(10),3,5,8,11(15)-pentaene-13-carboxylate (for synthesis, see EP 0254245). LC (Method 2):t R = 0.69 min; Mass spectrum (ESI+): m / z = 434 [M+H] + .

[0235] The intermediates summarized in the table below are (13S)-9-(2-chlorophenyl)-3-methyl-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]-Hexadeca-1(10),3,5,8,11(15)-pentaene-13-carboxylic acid or 9-(2-chlorophenyl)-3-methyl-16-thia-2,4,5,8-tetra-azatetracyclo[8.6.0.0 2,6 .0 11,15] by following a procedure similar to that described for intermediate 5 using hexadeca-1(10),3,5,8,11(15)-pentaene-13-carboxylic acid and the respective amine.

[0236] [Table 24]

[0237] Intermediate 28 9-(2-chlorophenyl)-3-ethyl-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]Hexadeca-1(10),3,5,8,11(15)-pentaene

[0238] [ka] The title compound can be obtained by following a procedure similar to that described in step 5 of intermediate 1 to obtain methyl 13-(2-chlorophenyl)-10-oxo-7-thia-9,12-diazatricyclo[6.5.0.0]. 2,6 ]trideca-1(8),2(6),12-triene-4-carboxylate and propanohydrazide, and methyl 9-(2-chlorophenyl)-3-ethyl-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]hexadeca-1(10),3,5,8,11(15)-pentaene-13-carboxylate is obtained. The ester is then saponified by following a procedure similar to that described for intermediate 2, and the resulting carboxylic acid is converted to the title compound by following a procedure similar to that described for intermediate 5. Alternatively, methyl 9-(2-chlorophenyl)-3-ethyl-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15]Hexadeca-1(10),3,5,8,11(15)-pentaene-13-carboxylate can be prepared from methyl 13-(2-chlorophenyl)-10-sulfanylidene-7-thia-9,12-diazatricyclo[6.5.0.0] according to a procedure similar to that reported in Arzneimittelforschung 1978, 28, 1153-8 or U.S. Pat. No. 7,015,213. 2,6 ]Trideca-1(8),2(6),12-triene-4-carboxylate. LC (Method 2):t R = 0.82 min; Mass spectrum (ESI+): m / z = 482 [M+H] + .

[0239] Intermediate 29 9-(2-chlorophenyl)-3-propyl-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]-Hexadeca-1(10),3,5,8,11(15)-pentaene

[0240] [ka] The title compound can be obtained by following a procedure similar to that described in step 5 of intermediate 1 to obtain methyl 13-(2-chlorophenyl)-10-oxo-7-thia-9,12-diazatricyclo[6.5.0.0]. 2,6 ]trideca-1(8),2(6),12-triene-4-carboxylate and butyric acid hydrazide, and methyl 9-(2-chlorophenyl)-3-propyl-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15]hexadeca-1(10),3,5,8,11(15)-pentaene-13-carboxylate is obtained. The ester is then saponified by following a procedure similar to that described for intermediate 2, and the resulting carboxylic acid is converted to the title compound by following a procedure similar to that described for intermediate 5. Alternatively, methyl 9-(2-chlorophenyl)-3-propyl-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]Hexadeca-1(10),3,5,8,11(15)-pentaene-13-carboxylate can be prepared from methyl 13-(2-chlorophenyl)-10-sulfanylidene-7-thia-9,12-diazatricyclo[6.5.0.0] according to a procedure similar to that reported in Arzneimittelforschung 1978, 28, 1153-8 or U.S. Pat. No. 7,015,213. 2,6 ]Trideca-1(8),2(6),12-triene-4-carboxylate. LC (Method 2):t R = 0.87 min; Mass spectrum (ESI+): m / z = 496 [M+H] + .

[0241] Intermediate 30 9-(2-chlorophenyl)-3-cyclopropyl-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]-Hexadeca-1(10),3,5,8,11(15)-pentaene

[0242] [ka] The title compound can be obtained by following a procedure similar to that described in step 5 of intermediate 1 to obtain methyl 13-(2-chlorophenyl)-10-oxo-7-thia-9,12-diazatricyclo[6.5.0.0]. 2,6]trideca-1(8),2(6),12-triene-4-carboxylate and cyclopropanecarbohydrazide, and methyl 9-(2-chlorophenyl)-3-cyclopropyl-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]hexadeca-1(10),3,5,8,11(15)-pentaene-13-carboxylate is obtained. The ester is then saponified by following a procedure similar to that described for intermediate 2, and the resulting carboxylic acid is converted to the title compound by following a procedure similar to that described for intermediate 5. Alternatively, methyl 9-(2-chlorophenyl)-3-cyclopropyl-16-thia-2,4,5,8-tetraazatetracyclo-[8.6.0.0 2,6 .0 11,15 ]Hexadeca-1(10),3,5,8,11(15)-pentaene-13-carboxylate can be prepared from methyl 13-(2-chlorophenyl)-10-sulfanylidene-7-thia-9,12-diazatricyclo[6.5.0.0] according to a procedure similar to that reported in Arzneimittelforschung 1978, 28, 1153-8 or U.S. Pat. No. 7,015,213. 2,6 ]Trideca-1(8),2(6),12-triene-4-carboxylate. LC (Method 2):t R = 0.83 min; Mass spectrum (ESI+): m / z = 494 [M+H] + .

[0243] Intermediate 31 (3-methyl-9-[2-(methylsulfanyl)phenyl]-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2 , 6 .0 11 , 15 ]-Hexadeca-1(10),3,5,11(15)-pentaene

[0244] [ka] 9-(2-Bromophenyl)-3-methyl-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2 , 6 .0 11 , 15 ]-Hexadeca-1(10),3,5,8,11(15)-pentaene (135 mg), copper(I) iodide (50 mg) and DABCO (59 mg) are dissolved in anhydrous DMSO (2.0 mL). The reaction mixture is stirred under argon at 130° C. for 16 h. The mixture is diluted with acetonitrile and purified by reverse phase chromatography (HPLC; ACN / water / TFA) to give the title compound. LC (Method 2):t R = 0.74 min; Mass Spectrum (ESI + ):m / z=480[M+H] + .

[0245] Example Synthesis: Example 1 9-(2-chlorophenyl)-3-methyl-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]-Hexadeca-1(10),3,5,11(15)-tetraene

[0246] [ka] 9-(2-chlorophenyl)-3-methyl-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15]To a solution of hexadeca-1(10),3,5,8,11(15)-pentaene (200 mg) in DCE (1 mL) is added successively at room temperature NaBH4 (32 mg) and HCl (4 M in water; 0.26 mL). The mixture is stirred for 2 h, and then additional portions of NaBH4 (16 mg) and HCl (4 mol / L in water; 0.26 mL) are added. The reaction is further stirred at room temperature until complete. If the reaction is not complete, additional NaBH4 and HCl are added. Aqueous NaHCO3 is added and the resulting mixture is extracted with DCM (3x). The combined organic extracts are dried (Na2SO4) and concentrated. The residue is purified by reverse phase chromatography (HPLC; ACN / water / aqueous ammonia) to give the title compound as a racemic mixture of two diastereomers (approximately 60 / 40). LC (Method 2):t R = 0.72 min; Mass Spectrum (ESI + ):m / z=470[M+H] + .

[0247] (Examples 2 and 3) (9R,13S)-9-(2-chlorophenyl)-3-methyl-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2 , 6 .0 11 , 15 ]-Hexadeca-1(10),3,5,11(15)-tetraene (Example 2) and (9S,13S)-9-(2-chlorophenyl)-3-methyl-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2 , 6 .0 11 , 15 ]-Hexadeca-1(10),3,5,11(15)-tetraene (Example 3)

[0248] [ka] (13S)-9-(2-chlorophenyl)-3-methyl-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetra-cyclo[8.6.0.0 2,6 .0 11,15 ] To a solution of hexadeca-1(10),3,5,8,11(15)-pentaene (1.00 g) in DCM (25 mL) is added sequentially HCl (4 M in water, 1.07 mL) and NaBH4 (323 mg) at room temperature. The mixture is stirred for 1 h until completion. The mixture is diluted with water and aqueous HCl (1 M) until a pH of 8-9 is achieved and extracted with DCM (2x). The combined organic extracts are dried (Na2SO4) and concentrated. Repeated purification of the residue by reverse phase chromatography (HPLC; ACN / water / aqueous TFA) gives the TFA salts of the diastereomers, which are completely separated. These diastereomers can be liberated from their salt forms by adding aqueous NaHCO3, extracting the resulting mixture with DCM, and concentrating the organic extract to give the title compound. Example 2: LC (Method 2): R = 0.72 min; Mass Spectrum (ESI + ):m / z=470[M+H] + ; Example 3: LC (Method 2): R = 0.73 min; Mass Spectrum (ESI + ):m / z=470[M+H] + .

[0249] Example 4 (9R,13S)-9-(2-chlorophenyl)-3-methyl-13-[(2S)-2-methylmorpholine-4-carbonyl]-16-thia-2,4,5,8-tetraazatetracyclo-[8.6.0.0 2 , 6 .0 11 , 15 ]Hexadeca-1(10),3,5,11(15)-tetraene

[0250] [ka] The title compound was prepared by a procedure similar to that described for intermediate 5, from (9R,13S)-9-(2-chlorophenyl)-3-methyl-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ] prepared from hexadeca-1(10),3,5,11(15)-tetraene-13-carboxylic acid and (2S)-2-methyl-morpholine hydrochloride. LC (method 4):t R = 0.50 min; Mass Spectrum (ESI + ):m / z=484[M+H] + .

[0251] The examples (Ex.) summarized in the table below are 9-(2-chlorophenyl)-3-methyl-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]These compounds can be obtained by following procedures similar to those described for intermediate 5 using the individual stereoisomers or mixtures of stereoisomers of hexadeca-1(10),3,5,11(15)-tetraene-13-carboxylic acid and the respective amines. SFC separation is used to obtain Examples 11 and 12 [Column: Chiral Art® Amylose-SA (10 mm x 250 mm, 5 μm); Column temperature: 40° C.; Flow rate: 10 mL / min; BPR: 150 bar; Injection volume: 250 μL (2.5 mg); Isocratic conditions: 70:30 CO2:MeOH (20 mM NH3)], and Examples 13 and 14 [Column: Chiralpak® IA (10 mm x 250 mm, 5 μm); Column temperature: 40° C.; Flow rate: 10 mL / min; BPR: 150 bar; Injection volume: 200 μL (2 mg); Isocratic conditions: 65:35 CO2:EtOH (20 mM NH3)].

[0252] [Table 25] JPEG2024099528000113.jpg227169 JPEG2024099528000114.jpg220169 JPEG2024099528000115.jpg226169 JPEG2024099528000116.jpg230169 JPEG2024099528000117.jpg227169 JPEG2024099528000118.jpg224169 JPEG2024099528000119.jpg226169 JPEG2024099528000120.jpg231169 JPEG2024099528000121.jpg233169 JPEG2024099528000122.jpg229169 JPEG2024099528000123.jpg234169 JPEG2024099528000124.jpg167169 JPEG2024099528000125.jpg239169 JPEG2024099528000126.jpg152169 JPEG2024099528000127.jpg166169 JPEG2024099528000128.jpg229169

[0253] (Example 52) 9-(4-chlorophenyl)-3-methyl-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2 ,6 .0 11 , 15 ]Hexadeca-1(10),3,5,11(15)-tetraene

[0254] [ka] The title compound was prepared according to a procedure similar to that described in Example 1, from 9-(4-chlorophenyl)-3-methyl-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2 , 6 .0 11 , 15 ]Hexadeca-1(10),3,5,8,11(15)-pentaene. LC (Method 2):t R = 0.72 min; Mass spectrum (ESI+): m / z = 470 [M+H] + .

[0255] (Example 53) 9-(2-Ethylphenyl)-3-methyl-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2 , 6 .0 11 , 15 ]Hexadeca-1(10),3,5,11(15)-tetraene

[0256] [ka] The title compound was prepared according to a procedure similar to that described in Example 1, from 9-(2-ethylphenyl)-3-methyl-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2 , 6 .0 11 , 15 ]Hexadeca-1(10),3,5,8,11(15)-pentaene. LC (Method 2):t R=0.72 / 0.74 min (diastereomers); Mass spectrum (ESI+): m / z=464 [M+H] + .

[0257] (Example 54) 9-(2-Methoxyphenyl)-3-methyl-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2 , 6 .0 11 , 15 ]-Hexadeca-1(10),3,5,11(15)-tetraene

[0258] [ka] The title compound was prepared according to a procedure similar to that described in Example 1, from 9-(2-methoxyphenyl)-3-methyl-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2 , 6 .0 11 , 15 ]Hexadeca-1(10),3,5,8,11(15)-pentaene. LC (Method 2):t R = 0.68 min; Mass spectrum (ESI+): m / z = 466 [M+H] + .

[0259] (Example 55) 9-(2-Fluorophenyl)-3-methyl-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2 , 6 .0 11 , 15 ]Hexadeca-1(10),3,5,11(15)-tetraene

[0260] [ka] The title compound was prepared according to a procedure similar to that described in Example 1, from 9-(2-fluorophenyl)-3-methyl-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]Hexadeca-1(10),3,5,8,11(15)-pentaene. LC (Method 2):t R =0.78 / 0.79 min (diastereomers); Mass spectrum (ESI+): m / z=454 [M+H] + .

[0261] (Example 56) 3-Methyl-13-(morpholine-4-carbonyl)-9-[2-(trifluoromethyl)phenyl]-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2 , 6 .0 11 , 15 ]-Hexadeca-1(10),3,5,11(15)-tetraene

[0262] [ka] The title compound was prepared according to a procedure similar to that described in Example 1, from 3-methyl-13-(morpholine-4-carbonyl)-9-[2-(trifluoromethyl)phenyl]-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]Hexadeca-1(10),3,5,8,11(15)-pentaene. LC (Method 2):t R = 0.76 min; Mass spectrum (ESI+): m / z = 504 [M+H] + .

[0263] (Example 57) 9-(2-Bromophenyl)-3-methyl-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2 , 6 .0 11 ,15 ]Hexadeca-1(10),3,5,11(15)-tetraene

[0264] [ka] The title compound was prepared according to a procedure similar to that described in Example 1, from 9-(2-bromophenyl)-3-methyl-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]Prepared from hexadeca-1(10),3,5,8,11(15)-pentaene. LC (Method 2):t R =0.71 / 0.72 min (diastereomers); Mass spectrum (ESI+): m / z=514 / 516 (Br) [M+H] + .

[0265] (Example 58) 9-(3,5-difluorophenyl)-3-methyl-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2 , 6 .0 11 , 15 ]-Hexadeca-1(10),3,5,11(15)-tetraene

[0266] [ka] The title compound was prepared according to a procedure similar to that described in Example 1, from 9-(3,5-difluorophenyl)-3-methyl-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]Hexadeca-1(10),3,5,8,11(15)-pentaene. LC (Method 2):t R = 0.72 min; Mass spectrum (ESI+): m / z = 472 [M+H] + .

[0267] (Example 59) 9-(2-cyclopropylphenyl)-3-methyl-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2 , 6 .0 11 , 15 ]-Hexadeca-1(10),3,5,11(15)-tetraene

[0268] [ka] The title compound was prepared according to a procedure similar to that described in Example 1, from 9-(2-cyclopropylphenyl)-3-methyl-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]Hexadeca-1(10),3,5,8,11(15)-pentaene. LC (Method 2):t R =0.73 / 0.75 min (diastereomers); Mass spectrum (ESI+): m / z=476 [M+H] + .

[0269] (Example 60) {2-[3-methyl-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2 , 6 .0 11 , 15 ]Hexadeca-1(10),3,5,11(15)-tetraen-9-yl]phenyl}methanol

[0270] [ka] The title compound was prepared according to a procedure similar to that described in Example 1, by the synthesis of {2-[3-methyl-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo-[8.6.0.0 2,6 .0 11,15]hexadeca-1(10),3,5,8,11(15)-pentaen-9-yl]phenyl}methanol. LC (Method 2): R =0.64 / 0.65 min (diastereomers); Mass spectrum (ESI+): m / z=466 [M+H] + .

[0271] (Example 61) 2-[3-methyl-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2 , 6 .0 11 , 15 ]Hexadeca-1(10),3,5,11(15)-tetraen-9-yl]phenol

[0272] [ka] The title compound was prepared according to a procedure similar to that described in Example 1, by the synthesis of 2-[3-methyl-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo-[8.6.0.0 2,6 .0 11,15 ]hexadeca-1(10),3,5,8,11(15)-pentaen-9-yl]phenol. LC (Method 1): R =0.74 / 0.75 min (diastereomers); Mass spectrum (ESI+): m / z=452 [M+H] + .

[0273] (Example 62) 9-(2-chloro-5-methoxyphenyl)-3-methyl-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo-[8.6.0.0 2 , 6 .0 11 , 15 ]Hexadeca-1(10),3,5,11(15)-tetraene

[0274] [ka] The title compound was prepared according to a procedure similar to that described in Example 1, from 9-(2-chloro-5-methoxyphenyl)-3-methyl-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]Hexadeca-1(10),3,5,8,11(15)-pentaene. LC (Method 2):t R = 0.73 min; Mass spectrum (ESI+): m / z = 500 [M+H] + .

[0275] (Example 63 and Example 64) (9R,13S)-3-Methyl-9-(2-methylphenyl)-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2 , 6 .0 11 , 15 ]-Hexadeca-1(10),3,5,11(15)-tetraene (Example 63) and (9S,13S)-3-Methyl-9-(2-methylphenyl)-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2 , 6 .0 11 , 15 ]-Hexadeca-1(10),3,5,11(15)-tetraene (Example 64)

[0276] [ka] The title compound was prepared according to a procedure similar to that described in Example 1, by the synthesis of (13S)-3-methyl-9-(2-methylphenyl)-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15]Hexadeca-1(10),3,5,8,11(15)-pentaene. The diastereomers are purified by reverse phase chromatography (HPLC; ACN / water / TFA) to give the title compound. Example 63: LC (Method 2): R = 0.71 min; Mass spectrum (ESI+): m / z = 450 [M+H] + ; Example 64: LC (Method 2): R = 0.69 min; Mass spectrum (ESI+): m / z = 450 [M+H] + .

[0277] (Example 65) (13S)-9-(2-chlorophenyl)-N-(1-hydroxy-2-methylpropan-2-yl)-3-methyl-16-thia-2,4,5,8-tetraazatetracyclo-[8.6.0.0 2 , 6 .0 11 , 15 ]Hexadeca-1(10),3,5,11(15)-tetraene-13-carboxamide

[0278] [ka] The title compound was prepared according to a procedure similar to that described in Example 1, by the synthesis of (13S)-9-(2-chlorophenyl)-N-(1-hydroxy-2-methylpropan-2-yl)-3-methyl-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]Hexadeca-1(10),3,5,8,11(15)-pentaene-13-carboxamide. LC (Method 2):t R = 0.72 min; Mass spectrum (ESI+): m / z = 472 [M+H] + .

[0279] (Example 66) 13-{5-azaspiro[2.5]octane-5-carbonyl}-9-(2-chlorophenyl)-3-methyl-16-thia-2,4,5,8-tetraazatetracyclo-[8.6.0.0 2 , 6 .0 11 , 15 ]Hexadeca-1(10),3,5,11(15)-tetraene

[0280] [ka] The title compound was prepared according to a procedure similar to that described in Example 1, from 13-{5-azaspiro[2.5]octane-5-carbonyl}-9-(2-chlorophenyl)-3-methyl-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2 , 6 .0 11 , 15 ]Hexadeca-1(10),3,5,11(15)-pentaene. LC (Method 1):t R = 0.99 min; Mass spectrum (ESI+): m / z = 494 [M+H] + .

[0281] The examples summarized in the table below were prepared by following a procedure similar to that described in Example 1, to obtain 9-(2-chlorophenyl)-3-ethyl-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2 , 6 .0 11 , 15]Hexadeca-1(10),3,5,11(15)-pentaene. The individual stereoisomers are obtained by chiral SFC: a first separation to obtain Examples 68 and 69 [column: Chiralpak® IA (20 mm x 250 mm, 5 μm); column temperature: 40° C.; flow rate: 60 mL / min; BPR: 150 bar; injection volume: 250 μL (2.5 mg); isocratic conditions: 70:30 CO2:EtOH (20 mM NH3)], then a second separation of the mixed fractions to obtain Reference Examples 70 and 71 [column: Chiral Art® Amylose-SA (10 mm x 250 mm, 5 μm); column temperature: 40° C.; flow rate: 10 mL / min; BPR: 150 bar; injection volume: 200 μL (4 mg); isocratic conditions: 80:20 CO2:MeOH (20 mM NH3)].

[0282] [Table 26] JPEG2024099528000144.jpg149166 (Example 72 and Example 73) (9S,13S)-9-(2-chlorophenyl)-3-methyl-N,N-dipropyl-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2 , 6 .0 11 , 15 ]Hexadeca-1(10),3,5,11(15)-tetraene-13-carboxamide (Example 72) and (9R,13S)-9-(2-chlorophenyl)-3-methyl-N,N-dipropyl-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2 , 6 .0 11 , 15 ]Hexadeca-1(10),3,5,11(15)-tetraene-13-carboxamide (Example 73)

[0283] [ka] The title compound was prepared according to a procedure similar to that described in Example 1, by the synthesis of (13S)-9-(2-chlorophenyl)-3-methyl-N,N-dipropyl-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2,6 .0 11,15 ]Hexadeca-1(10),3,5,11(15)-tetraene-13-carboxamide. The diastereomers are separated by chiral SFC [Column: Chiral Art® Amylose-SA (10 mm x 250 mm, 5 μm); Column temperature: 40 °C; Flow rate: 10 mL / min; BPR: 150 bar; Injection volume: 100 μL (2 mg); Isocratic conditions: 75:25 CO2:MeOH (20 mM NH3)]. Example 72: LC (Method 7): R = 2.10 min; Mass spectrum (ESI+): m / z = 484 [M+H] + ; Example 73: LC (Method 7): R = 3.02 min; Mass spectrum (ESI+): m / z = 484 [M+H] + .

[0284] The examples summarized in the table below show the preparation of 3-methyl-13-(morpholine-4-carbonyl)-9-phenyl-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0] by following a procedure similar to that described in Example 1. 2,6 .0 11,15]Hexadeca-1(10),3,5,8,11(15)-pentaene. The trans and cis diastereomers are separated by reversed-phase chromatography (HPLC; ACN / water / TFA). The separated diastereomeric racemates can be further separated into individual enantiomers by chiral SFC to give Example 75 and Example 76 [Column: Chiralpak IA (20 mm x 250 mm, 5 μm); Column temperature: 40 ° C; Flow rate: 10 mL / min; BPR: 150 bar; Injection volume: 200 μL (3 mg); Isocratic conditions: 70: 30 scCO2: MeOH (20 mM NH3)], and Reference Example 77 and Example 78 [Column: CHIRAL ART (registered trademark) Cellulose-SB (10 × 250 mm, 5 μm); Column temperature: 40 ° C; Flow rate: 10 mL / min; BPR: 150 bar; Injection volume: 200 μL (2 mg); Isocratic conditions: 70: 30 CO2: iPrOH (20 mM NH3)].

[0285] [Table 27] JPEG2024099528000147.jpg139168

[0286] (Example 79) 3-Methyl-9-[2-(methylsulfanyl)phenyl]-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2 , 6 .0 11 , 15 ]Hexadeca-1(10),3,5,11(15)-tetraene

[0287] [ka] The title compound was prepared according to a procedure similar to that described in Example 1, using the formula (3-methyl-9-[2-(methylsulfanyl)phenyl]-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2 , 6 .0 11 , 15 ]Hexadeca-1(10),3,5,11(15)-pentaene. LC (Method 2):t R =0.70 / 0.71 min (diastereomers); Mass spectrum (ESI+): m / z=482 [M+H] + .

[0288] (Example 80) 9-(2-chlorophenyl)-13-(morpholine-4-carbonyl)-3-propyl-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2 , 6 .0 11 , 15 ]Hexadeca-1(10),3,5,11(15)-tetraene

[0289] [ka] The title compound was prepared according to a procedure similar to that described in Example 1, from 9-(2-chlorophenyl)-13-(morpholine-4-carbonyl)-3-propyl-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2 , 6 .0 11 , 15 ]Hexadeca-1(10),3,5,11(15)-pentaene. LC (Method 2):t R =0.77 / 0.78 min (diastereomers); Mass spectrum (ESI+): m / z=498 [M+H] + .

[0290] (Example 81) 9-(2-chlorophenyl)-3-cyclopropyl-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2 , 6 .0 11 , 15 ]Hexadeca-1(10),3,5,11(15)-tetraene

[0291] [ka] The title compound was prepared according to a procedure similar to that described in Example 1, from 9-(2-chlorophenyl)-3-cyclopropyl-13-(morpholine-4-carbonyl)-16-thia-2,4,5,8-tetraazatetracyclo[8.6.0.0 2 , 6 .0 11 , 15 ]Hexadeca-1(10),3,5,11(15)-pentaene. LC (Method 2):t R = 0.75 min; Mass spectrum (ESI+): m / z = 496 [M+H] + .

Claims

1. Compound of formula (I.0) (In the formula, R 1 is C 1-4 -alkyl (optionally substituted with 1 to 3 F) and C 3-4 -cycloalkyl, R 2 are F, Cl, Br, I, C 1-4 -Alkyl, C 3-4 -Cycloalkyl, -CN, -CONH 2 , -CONH(C 1-4 -alkyl), -CON(C 1-4 -alkyl) 2 , -COOH, -COO-C 1-4 -Alkyl, OH, -O-C 1-4 -alkyl, and -S(O) r -C 1-4 - alkyl (r=0, 1 or 2), the C 1-4 -alkyl R 2 group may be optionally substituted by one to three F or by one CN, one OH or one —O—C 1-4 -alkyl; The —O—C 1-4 -alkyl R 2 group is optionally substituted by 1 to 3 F, n is selected from the group consisting of 0, 1, 2 and 3; R 3 is H, and C 1-4 - alkyl (optionally substituted by 1 to 5 F), R 4 is C 1-6 - alkyl, C 1-6 -Alkyl is optionally substituted by 1 to 3 F; -CN, -CONH 2 , -CONH(C 1-4 -alkyl), -CON(C 1-4 -alkyl) 2 , -COOH, -COO-C 1-4 -Alkyl, C 1-3 -alkyl-CO-NH-, C 1-3 -Alkyl-S(=O) 2 -NH-, OH and -O-C 1-3 -alkyl (optionally substituted by 1-3 F); or R 4 is -C 0-3 -Alkylene-C 3-10 -cycloalkyl and -C 0-3 -Alkylene-C 3-10 -heterocyclyl, The alkylene is selected from F and CH 3 may be substituted with 1 to 2 substituents selected from One of the alkylene groups >CH 2 The two H atoms in the group are ethylene (-CH 2 -CH 2 -) bridge, the cyclopropylene moiety > C(-CH 2 -CH 2 -), The cycloalkyl and heterocyclyl are saturated monocyclic or bicyclic ring systems, The heterocyclyl is N, NH, >N(C 1-4 -alkyl), >NCO(C 1-4 -alkyl), >NS(=O) 2 (C 1-4 -alkyl) and O, and contains 1 to 2 ring members independently selected from >C=O and >S(=O) r (r=0, 1 or 2), However, the heterocyclyl may have N-N, N-O and N-S (=O) between the ring members. r=1,2 does not contain heteroatom-heteroatom bonds other than The cycloalkyl and heterocyclyl may be substituted with 1 to 2 F, and may be substituted with Cl, —CN, —CONH 2 , -CONH(C 1-4 -alkyl), -CON(C 1-4 -alkyl) 2 , -COOH, -COO-C 1-4 -Alkyl, OH, -O-C 1-3 - alkyl (optionally substituted by 1 to 3 F), and C 1-4 -Alkyl (with 1 to 3 F or -CN, OH, -O-C 1-4 -alkyl); or R 4 is -C 0-3 -alkylene-phenyl and -C 0-3 -alkylene-heteroaryl; The alkylene is selected from F and CH 3 may be substituted with 1 to 2 substituents selected from One of the alkylene groups >CH 2 The two H atoms in the group are ethylene (-CH 2 -CH 2 -) bridge, the cyclopropylene moiety > C(-CH 2 -CH 2 -), the heteroaryl is a 5-membered monocyclic ring containing one ring member selected from N, NH, O and S, optionally further containing 1-2 N ring members, or a 6-membered monocyclic ring containing 1-2 N ring members; The phenyl and heteroaryl are F, Cl, Br, C 3-4 -Cycloalkyl, -CN, -CONH 2 , -CONH(C 1-4 -alkyl), -CON(C 1-4 -alkyl) 2 , -COOH, -COO-C 1-4 -Alkyl, -NHCO-C 1-4 -Alkyl, -NHS(=O) 2 -C 1-4 -Alkyl, -S(=O) r -C 1-4 -alkyl (r=0, 1 or 2), -O-C 1-4 - alkyl (optionally substituted by 1 to 3 F), and C 1-4 -Alkyl (with 1 to 3 F, or -CN, OH and -O-C 1-4 -alkyl) or a pharma- ceutically acceptable salt thereof.

2. R 1 But, CH 3 , C.H. 2 CH 3 , C.H. 2 CH 2 CH 3 , C.H.F. 2 , C.F. 3 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, wherein the compound is selected from the group consisting of: cyclopropyl, cyclopropyl, and cyclopropyl.

3. The compound of claim 1 or a pharma- ceutically acceptable salt thereof, wherein R1 is CH3.

4. R 2 is selected from the group consisting of F, Cl, Br, CH3, CH2CH3, cyclopropyl, CF3, CH2OH, OH, OCH3, and S-CH3; n is selected from the group consisting of 0, 1 and 2; 2. The compound of claim 1 or a pharma- ceutically acceptable salt thereof.

5. R 2 is selected from the group consisting of F, Cl and Br; n is 1; 2. The compound of claim 1 or a pharma- ceutically acceptable salt thereof.

6. R2 is Cl, n is 1; 2. The compound of claim 1 or a pharma- ceutically acceptable salt thereof.

7. R 1 is CH 3 , R 2 , n, and the phenyl substitution pattern are such that the resulting substituted phenyl ring shown in formula (I.0) is is selected so that 2. The compound of claim 1 or a pharma- ceutically acceptable salt thereof.

8. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, wherein R3 is selected from the group consisting of H, CH3, and CH2CH2CH3.

9. The compound according to claim 1, wherein R 4 is selected from the group consisting of C 1-4 -alkyl; C 1-4 -alkyl is optionally substituted by 1 to 3 F and by one substituent selected from -CN, -CONH 2 , -COOH, OH and -O-C 1-2 -alkyl, optionally substituted by 1 to 3 F, 2. The compound of claim 1 or a pharma- ceutically acceptable salt thereof.

10. The compound according to claim 1, wherein R 4 is selected from the group consisting of C 1-4 -alkyl; 2. The compound according to claim 1, or a pharma- ceutically acceptable salt thereof, wherein C1-4-alkyl is optionally substituted by one substituent selected from F, OH and OCF3.

11. R 4 is 2. The compound of claim 1, selected from the group consisting of: or a pharma- ceutically acceptable salt thereof.

12. The compound according to claim 1, wherein R 4 is selected from the group consisting of -C 0-1 -alkylene-C 3-6 -cycloalkyl; The cycloalkyl is a saturated monocyclic or bicyclic ring system, the cycloalkyl is optionally substituted by 1 to 2 F and by one CH 3 or CH 2 CH 3 ; 2. The compound of claim 1 or a pharma- ceutically acceptable salt thereof.

13. R 4 is 2. The compound of claim 1, selected from the group consisting of: or a pharma- ceutically acceptable salt thereof.

14. The compound according to claim 1, wherein R 4 is selected from the group consisting of —C 0-2 -alkylene-phenyl and —C 0-2 -alkylene-heteroaryl; The alkylene may be substituted with 1 to 2 CH 3 ; two H atoms of one >CH 2 group of said alkylene may be replaced by an ethylene (-CH 2 -CH 2 -) bridge to form a cyclopropylene moiety >C(-CH 2 -CH 2 -), the heteroaryl is a 5-membered monocyclic ring containing one ring member selected from N, NH, O and S, optionally containing one further N ring member, or a 6-membered monocyclic ring containing 1-2 N ring members; said phenyl and heteroaryl are optionally substituted by 1 to 3 substituents independently selected from F, Cl, Br, -CN, -O-Ci-3-alkyl (optionally substituted by 1 to 3 F) and Ci-3-alkyl (optionally substituted by 1 to 3 F) or by one substituent selected from -CN and -O-Ci-2-alkyl, 2. The compound of claim 1 or a pharma- ceutically acceptable salt thereof.

15. R 4 is 2. The compound of claim 1, selected from the group consisting of: or a pharma- ceutically acceptable salt thereof.

16. The stereochemistry of the compound is of formula (I.1) 2. The compound of claim 1 or a pharma- ceutically acceptable salt thereof.

17. 2. The compound of claim 1, selected from the group consisting of: or a pharma- ceutically acceptable salt thereof.

18. A pharma- ceutically acceptable salt of the compound according to any one of claims 1 to 16.

19. The compound described in claim 17, which is:

20. The compound described in claim 17, which is:

21. The compound described in claim 17, which is:

22. The compound described in claim 17, which is:

23. The compound described in claim 17, which is:

24. The compound described in claim 17, which is:

25. The compound described in claim 17, which is:

26. A pharma- ceutically acceptable salt of the compound of claim 17, wherein the compound is A pharma- ceutically acceptable salt thereof, 27. A pharma- ceutically acceptable salt of the compound of claim 17, wherein the compound is A pharma- ceutically acceptable salt thereof, 28. A pharma- ceutically acceptable salt of the compound of claim 17, wherein the compound is A pharma- ceutically acceptable salt thereof, 29. A pharma- ceutically acceptable salt of the compound of claim 17, wherein the compound is A pharma- ceutically acceptable salt thereof, 30. A pharma- ceutically acceptable salt of the compound of claim 17, wherein the compound is A pharma- ceutically acceptable salt thereof, 31. A pharma- ceutically acceptable salt of the compound of claim 17, wherein the compound is A pharma- ceutically acceptable salt thereof, 32. A pharma- ceutically acceptable salt of the compound of claim 17, wherein the compound is A pharma- ceutically acceptable salt thereof,

33. A pharmaceutical composition comprising one or more compounds according to any one of claims 1 to 17 or 19 to 25, and / or one or more pharma- ceutically acceptable salts according to any one of claims 18 or 26 to 32, optionally together with one or more inert carriers and / or diluents.

34. A pharmaceutical composition comprising one or more compounds according to any one of claims 1 to 17 or 19 to 25, and / or one or more pharma- ceutically acceptable salts according to any one of claims 18 or 26 to 32, and one or more additional therapeutic agents, optionally together with one or more inert carriers and / or diluents.

35. 35. The pharmaceutical composition of claim 34, wherein the one or more additional therapeutic agents are selected from the group consisting of antidiabetic agents, agents for the treatment of overweight and / or obesity, agents for the treatment of hypertension, heart failure and / or atherosclerosis, agents for the treatment of eye diseases, and agents for the treatment of allergy- and inflammation-related conditions and diseases.

36. A pharmaceutical composition described in any one of claims 33 to 35 for preventing or treating an eye disease.

37. The pharmaceutical composition described in claim 36, wherein the eye disease to be prevented or treated is selected from the group consisting of diabetic macular edema, dry and exudative age-related macular degeneration, geographic atrophy and nonexudative choroidal neovascularization.

38. A pharmaceutical composition according to any one of claims 33 to 35 for preventing or treating conditions and diseases associated with allergy and inflammation.

39. The pharmaceutical composition of claim 38, wherein the allergy- and inflammation-related condition and disease to be prevented or treated is urticaria or NASH.

40. 36. Use of a compound according to any one of claims 1 to 17 or 19 to 25, or a pharma- ceutically acceptable salt according to any one of claims 18 or 26 to 32, in the preparation of a medicament for preventing or treating an eye disease.

41. The use described in claim 40, wherein the eye disease to be prevented or treated is selected from the group consisting of diabetic macular edema, dry and exudative age-related macular degeneration, geographic atrophy and nonexudative choroidal neovascularization.

42. Use of a compound according to any one of claims 1 to 17 or 19 to 25, or a pharma- ceutically acceptable salt according to any one of claims 18 or 26 to 32, in the preparation of a medicament for preventing or treating conditions and diseases associated with allergy and inflammation.

43. The use of claim 42, wherein the allergy- and inflammation-related condition and disease to be prevented or treated is urticaria or NASH.